SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

9 Meters Biopharma, Inc. – ‘10-Q’ for 6/30/22 – ‘XML’

On:  Monday, 8/15/22, at 7:06am ET   ·   For:  6/30/22   ·   Accession #:  1551986-22-91   ·   File #:  1-37797

Previous ‘10-Q’:  ‘10-Q’ on 5/16/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/8/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 5/15/23 for 3/31/23   ·   5 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/15/22  9 Meters Biopharma, Inc.          10-Q        6/30/22   54:6M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.13M 
 2: EX-10.1     Material Contract                                   HTML    343K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     21K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
12: R1          Cover Page                                          HTML     70K 
13: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML     96K 
14: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     34K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML     77K 
                and Comprehensive Loss (Unaudited)                               
16: R5          Condensed Consolidated Statements of Stockholders?  HTML     74K 
                Equity (Unaudited)                                               
17: R6          Unaudited Condensed Consolidated Statements of      HTML     89K 
                Cash Flows                                                       
18: R7          Summary of Significant Accounting Policies          HTML     78K 
19: R8          Liquidity and Going Concern                         HTML     20K 
20: R9          Acquisition                                         HTML     20K 
21: R10         Related Party Transactions                          HTML     20K 
22: R11         Debt                                                HTML     24K 
23: R12         License Agreements                                  HTML     33K 
24: R13         Stockholders? Equity                                HTML     32K 
25: R14         Share-Based Compensation                            HTML    114K 
26: R15         Commitments and Contingencies                       HTML     30K 
27: R16         Subsequent Events                                   HTML     21K 
28: R17         Summary of Significant Accounting Policies          HTML     79K 
                (Policies)                                                       
29: R18         Summary of Significant Accounting Policies          HTML     41K 
                (Tables)                                                         
30: R19         Stockholders? Equity (Tables)                       HTML     28K 
31: R20         Share-Based Compensation (Tables)                   HTML    108K 
32: R21         Commitments and Contingencies (Tables)              HTML     23K 
33: R22         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     50K 
                Narrative (Details)                                              
34: R23         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     24K 
                Accrued Expenses (Details)                                       
35: R24         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     46K 
                Potential Dilutive Securities (Details)                          
36: R25         Liquidity and Going Concern (Details)               HTML     19K 
37: R26         Acquisition (Details)                               HTML     30K 
38: R27         Related Party Transactions (Details)                HTML     22K 
39: R28         Debt (Details)                                      HTML     40K 
40: R29         License Agreements (Details)                        HTML     99K 
41: R30         STOCKHOLDERS? EQUITY - Narrative (Details)          HTML     37K 
42: R31         STOCKHOLDERS? EQUITY - Reserve Shares of Common     HTML     25K 
                Stock (Details)                                                  
43: R32         SHARE-BASED COMPENSATION - Narrative (Details)      HTML    115K 
44: R33         SHARE-BASED COMPENSATION - Stock Option Activity    HTML    110K 
                (Details)                                                        
45: R34         SHARE-BASED COMPENSATION - Options Assumptions      HTML     46K 
                (Details)                                                        
46: R35         SHARED-BASED COMPENSATION - Financial Statements    HTML     24K 
                (Details)                                                        
47: R36         COMMITMENTS AND CONTINGENCIES - Narrative           HTML     47K 
                (Details)                                                        
48: R37         COMMITMENTS AND CONTINGENCIES - Future Minimum      HTML     29K 
                Payments for Operating Lease Liabilities (Details)               
49: R38         Subsequent Events (Details)                         HTML     37K 
52: XML         IDEA XML File -- Filing Summary                      XML     89K 
50: XML         XBRL Instance -- nmtr-20220630_htm                   XML   1.18M 
51: EXCEL       IDEA Workbook of Financial Reports                  XLSX    106K 
 8: EX-101.CAL  XBRL Calculations -- nmtr-20220630_cal               XML     96K 
 9: EX-101.DEF  XBRL Definitions -- nmtr-20220630_def                XML    416K 
10: EX-101.LAB  XBRL Labels -- nmtr-20220630_lab                     XML   1.15M 
11: EX-101.PRE  XBRL Presentations -- nmtr-20220630_pre              XML    661K 
 7: EX-101.SCH  XBRL Schema -- nmtr-20220630                         XSD    118K 
53: JSON        XBRL Instance as JSON Data -- MetaLinks              276±   413K 
54: ZIP         XBRL Zipped Folder -- 0001551986-22-000091-xbrl      Zip    532K

‘XML’   —   XBRL Instance — nmtr-20220630_htm

This Document is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xml:lang="en-US" xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nmtr="http://9meters.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="nmtr-20220630.xsd" xlink:type="simple"/>
<context id="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i561a0afe9ff04b959bba347becaf5714_I20220810">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2022-08-10 </instant>
</period>
</context>
<context id="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i10faeb84174c4fdfb2dba438580ab194_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i1b233687e104409199f09bb159ce94f3_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i1ad30f72f6084432a7afa6db908bc3d8_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="ib75b7f8361824b3299a692bbea1076cc_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="i2f260a3791444489a23f6305d3e0a348_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="i829c83d880ea4c4db4fdd42f05907bc1_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="i0077bbf3925941e7a7abaa0706eed2f2_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="i5bcb9dd2dc984102865532e65f8d2876_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="i6971608db72d415aa515b8bfffca0cd6_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="i43011da2aead48bd9f4cf099f8db4d66_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="i678eaa6a68af4f40a0438b9e84c52468_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="i60d9ddd634b64bfd83b0ad11334421d1_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="i2d01ef06217f49e18732c9bd0a775710_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ib47d3e0986df43958c3def03d1db4cea_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i71b778589cff47a897071b0ad0e2e936_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i706b2ae4393245d9b60d7122688533af_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i4662a20e990b4fcab6b236f1b3363200_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="ifb788d4de59e4f3daea12d3337766033_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="iaee7d2c90d4f47df971bd2f0bd6f72f4_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="i9c5baf0d76cb47d98dd9a47ab7b1a659_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="id6ec8051cf8040338440d6ed67131ac7_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="i1273166b31f14a28bb435260be02d93e_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="i8b758bf8f26f4f28ba9085b071ae03fc_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="i269aa8d981fc4d1d9e7e8c7c29b4d1da_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="i397f258f2fcf47f086d0c29d51188dfb_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="id479c133b0a149fd8878c46299c01b1b_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="id39b8404dbd74c75a23046d8777ebe66_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="if600423d126e45dcb47c204347979d89_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="ib38b36d8ace346ceb16938d0800c668b_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="i67bc54fcbc2e46ddadff383f2f0c5541_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i928878b584244700a596276e856c782a_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i4b42a002164b43bea0d7f189c71843c3_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="id794d4ca86224b4583b0ccd00d7f8b85_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="iefc3653a940b4b30ac2f0b2d0185223e_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="i795078817fa04a78822210551ff1c072_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="if38cffc404754accaf0dd23d052a4bb2_I20201002">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2020-10-02 </instant>
</period>
</context>
<context id="i16d10833d39241ada6a6297d1b37e1ef_I20200722">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:SunTrustRobinsonHumphreyMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-07-22 </instant>
</period>
</context>
<context id="if81448b87fcf45e6a4fb1925e6852af7_D20210330-20210330">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:PublicStockOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-30 </startDate>
<endDate> 2021-03-30 </endDate>
</period>
</context>
<context id="i301c4447b92b4fc7b2529ac826026bdf_I20210330">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:PublicStockOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-30 </instant>
</period>
</context>
<context id="id3b850aedc9742e0ac828a3c9a3fa186_D20210330-20210330">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:OverAllotmentOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-30 </startDate>
<endDate> 2021-03-30 </endDate>
</period>
</context>
<context id="i921a9f3f4aeb4f53b9d4365718e26462_D20210405-20210405">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:PublicStockOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-05 </startDate>
<endDate> 2021-04-05 </endDate>
</period>
</context>
<context id="i96f38e7cd45047458ef8b2003bee31d6_D20210330-20210330">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> nmtr:ChiefExecutiveOfficerChiefFinancialOfficerAndChairmanOfBoardOfDirectorsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:April2021OfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-30 </startDate>
<endDate> 2021-03-30 </endDate>
</period>
</context>
<context id="ie0f9f046f56942218c833782de58823c_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ic514e4e58330400e8e66a43125acf1bb_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="icb0bb2e204cd42ad85dcfde88fd781c2_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i0b54ca0f248c4c2180a64a364ba47626_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i6e3a31c2c9b4457c9cf9207f415868e6_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ibeefe042a512483fb8bedee119dfe7a2_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i6a03639bead34176a74878a7f897efd4_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i75f3dd9f369b4cd2b67866451920a537_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="iaeb54bd17810466d8a5e4677d26ef63e_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i57665d10321a448090db69d73c2676af_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="idf09e1f4c3c54b11be0b7b6edfeb120b_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:RDDEmployeesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i9624f11c6694442e8b86d7c0670c4810_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:RDDEmployeesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i7ef4bbc94d9248a3bc54214a8a401388_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="ic172df7fd57b4ed2a54c5e52a614e238_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i6c239bad1b6a48f6af846d6a4a0b884f_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i2fa9516d91b44161bbc7ebe5d6e85591_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i7a150b589a634d1a894dbf1c81a44e28_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i581f34bfe5944e758bbe4d055c506297_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="id0191e38b4864eecb9c3bef5f5816578_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i965ccab740a24bc5bd761270cd4aacb9_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i93f9bd1546344b0fb6ae7d79ec18e277_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ic0fedb90c4e24c208a5d4d200329e6b2_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice4Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i19cde8898ac44627afe21ef9c7d4df6a_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice4Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i20d88621004c451e887fca6445ab987f_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> nmtr:WarrantsExercisePrice4Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i8f80ec38c797462c94460631f26a5ac8_D20210719-20210719">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:LobesityLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-19 </startDate>
<endDate> 2021-07-19 </endDate>
</period>
</context>
<context id="ia57c0801b472477e970c138f50696801_I20210719">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:LobesityLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-07-19 </instant>
</period>
</context>
<context id="ic98cfc730ffd404c867befe1cc8978e7_I20210719">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:LobesityLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-07-19 </instant>
</period>
</context>
<context id="i70d54165797841aab839a7bb6f8cb2aa_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciAdvisorsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i43a2af6a9e3e4a75a459691d4e2ee7f3_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciAdvisorsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i3c68946b20ec41c490480e246357aba4_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciAdvisorsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i09064597d0eb438386926ff90cca0a2b_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciAdvisorsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i7f64e8aabc014f929102522aa260e9b1_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciCommunicationsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i357ce8577cab458db9ad05c0e2281b5b_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciCommunicationsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i1abf5da9853343ff85b2f34205be0f90_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciCommunicationsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ifcf1d2d3875c49e78693ff75bd2c31dd_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:LifeSciCommunicationsLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ib0eced5ce7c74957aa804c51c9415f47_I20200110">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-01-10 </instant>
</period>
</context>
<context id="i513c677c005d4719b6b2611cfb8d821a_D20200110-20200110">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-10 </startDate>
<endDate> 2020-01-10 </endDate>
</period>
</context>
<context id="ifbb87cf463714c00b4d05b1242040abf_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i39decf0bdd70488287e87612a951f343_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i220e71dc53a545dfa7ae595b11c88b4a_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="id7889241ee654c68a44582761f4be1cf_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AlbaAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2016-01-01 </startDate>
<endDate> 2016-12-31 </endDate>
</period>
</context>
<context id="if70accbc173f4cdfadb0ae1d83aea369_D20160101-20161231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> us-gaap:LicenseAndServiceMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AlbaAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2016-01-01 </startDate>
<endDate> 2016-12-31 </endDate>
</period>
</context>
<context id="i6115352c34e14b0898b4bbfb7f3ad2d1_D20130101-20131231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:SeachaidAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2013-01-01 </startDate>
<endDate> 2013-12-31 </endDate>
</period>
</context>
<context id="i6cd6d83970004f30b38f9c95197bc218_D20140101-20141231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2014-01-01 </startDate>
<endDate> 2014-12-31 </endDate>
</period>
</context>
<context id="i153dbae8537248c49190e3ec7bb0715d_D20140101-20141231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2014-01-01 </startDate>
<endDate> 2014-12-31 </endDate>
</period>
</context>
<context id="i038b6fb2db5f4a3db03d11e6dd970707_I20200506">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2020-05-06 </instant>
</period>
</context>
<context id="i5ca1e354b1ab4544b5978732be05e8c4_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> nmtr:UnitedStatesAndEuropeanUnionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AmunixLicenseGLP1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ibd28aaa15bb848869f9cd4e67c14ee03_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CN </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AmunixLicenseGLP1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i5b37ffe504664c04b9d65041e4e4ff35_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> nmtr:SouthKoreaAndEasternAsiaMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AmunixLicenseGLP2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="id06ba912253f4083bc6bef0d663e5bd0_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> nmtr:UnitedStatesAndEuropeanUnionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:AmunixLicenseGLP2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i72abcf3a41534573be4fd652117a6875_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:CedarsLicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ib996466d42d141c4af134baa567200ca_I20210719">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:LobesityLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:LobesityLicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-07-19 </instant>
</period>
</context>
<context id="i84d767bafe5345abb698cd0203027f61_I20210719">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:LobesityLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis"> nmtr:LobesityLicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-07-19 </instant>
</period>
</context>
<context id="i9f9ff1ca2e9b45f4b6297ce52b9367df_D20210816-20210816">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2021-08-16 </startDate>
<endDate> 2021-08-16 </endDate>
</period>
</context>
<context id="i19542c94858d4f24acbd5600b34107a2_D20220411-20220411">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:EuropeanBiomedicalResearchInstituteOfSalernoItalyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:LicenseAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-11 </startDate>
<endDate> 2022-04-11 </endDate>
</period>
</context>
<context id="ic9b00aabc8144d3bba98652d8844fce1_D20220411-20220411">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:EuropeanBiomedicalResearchInstituteOfSalernoItalyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> nmtr:CommonStockUnregisteredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:LicenseAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-11 </startDate>
<endDate> 2022-04-11 </endDate>
</period>
</context>
<context id="i3ad873508e374cbabbfeb8d6e2f6f107_D20220411-20220411">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:EuropeanBiomedicalResearchInstituteOfSalernoItalyMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-11 </startDate>
<endDate> 2022-04-11 </endDate>
</period>
</context>
<context id="i6fdb727dcd0c451bb9e6150fb5881d51_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:StockOptionsOutstandingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i50d2d2d25d354e2d9fac418a6e6f8752_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:StockOptionsOutstandingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="i2969c8cf7c564cbe8ad83fb88268cb40_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:WarrantsToPurchaseCommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i9f94dd28c5ee44c9a26c83cd74475922_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:WarrantsToPurchaseCommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i71ca31d8ff2b41d9acab4d38e431d956_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="ia0949f0f5ce14efc8723d5575f9b0212_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:TruistSecuritiesIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:AttheMarketOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ic95046b1850b4d0cbd64dc392881e2e4_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:TruistSecuritiesIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:AttheMarketOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i5c797acfda3d487abfe84bc25836d4fb_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:TruistSecuritiesIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:AttheMarketOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i4b6ca1a4a4b14b5db7e03ac606396726_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:TruistSecuritiesIncMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> nmtr:AttheMarketOfferingMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i2ee548f79fb84de391b927032650460d_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> nmtr:TruistSecuritiesIncMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i172c545015a041c08606c3a163282a0b_I20200430">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> nmtr:RDDPharmaLtd.Member </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-04-30 </instant>
</period>
</context>
<context id="i2ca92cabf9614150b24cc79abfd6b15b_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ic73df32ab27847eebda82c02a48e6a67_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i57eb1736d8cf4b8ea380b3b967089152_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="ibc1fd82c7be940aab649d2f9faeb2c06_D20210101-20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="ia7c98d043f1b43e089c81076d8e158ea_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2015StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i06d5468f6ab742c4921c6a98667cf93f_D20220101-20220101">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-01-01 </endDate>
</period>
</context>
<context id="id3ede521a8b540ed87f03eb5d9a0df51_D20210101-20210101">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-01-01 </endDate>
</period>
</context>
<context id="i5a440305ac384b5aac5312cd56e22bf9_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="iefb44601fd544951b828dc05536a64ba_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i82528eda4fa54d6999a3741878b8bc4a_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="id811568b4e844937b524098c0ec2c421_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ia942ac784750472cb192fa90ff75692a_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ib97914b7aeb54e318a556b53c46cc806_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i91fe66d5522a44a0bb2965da5556ff9d_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="i1e6759684bba42dc91d0c9397ca4db5b_D20210101-20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="i4e08de7aebc245afbc59ca2b5f28e190_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="iedc2390d12d84492ba74d904c0daaeb5_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="iec3ac3d6c4d54d75baec3438a8dc85d2_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i26d540e0d0734383af294884934fe325_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="icf8daca992f448fbbcd475fa2dd983ad_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i65a0a15ddc0c4991b23c9efc7e389b37_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2012OmnibusIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i93e7bcd2b8024c0fbcdbe6f410651dfe_I20220622">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-22 </instant>
</period>
</context>
<context id="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="idb705766e14544f8aef78c1869705805_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="ied0728b29d464b37b19c609377f024f0_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> nmtr:A2022StockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i31159c63fe234ee28d3f55c6fbff574a_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i562ff4c2ad8a4b0eaafc4a332fa277db_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="idc1585f8ea074a6488cbec7657fa7d0f_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="ica711ac772b04e35b3499b247062e197_D20210101-20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> nmtr:RDDOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="i0bc0477f0ff4420598406fa5ca5c002d_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="iac4cc2ff191c44a8b90c08111ea71239_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i65a1e1d787cb4d45b03e28d732eeb37e_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="i91ce303423f340ae903472ec1fff6018_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="i7578ca356aa5434590037bb60026cf65_I20200731">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<instant> 2020-07-31 </instant>
</period>
</context>
<context id="i5fbabc2e5ed54b499a13df6672bd1510_D20200701-20200731">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
</entity>
<period>
<startDate> 2020-07-01 </startDate>
<endDate> 2020-07-31 </endDate>
</period>
</context>
<context id="i0587c4d2148e4925b35c0e309b68874d_I20220715">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> nmtr:A2022ConvertibleNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-07-15 </instant>
</period>
</context>
<context id="if2048b92b8c1451e9e824a3abc2870d1_D20220715-20220715">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> nmtr:A2022ConvertibleNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis"> us-gaap:LondonInterbankOfferedRateLIBORMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-15 </startDate>
<endDate> 2022-07-15 </endDate>
</period>
</context>
<context id="ia5dfa9fe89cc49b0b71f63050e041a84_D20220715-20220715">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> nmtr:A2022ConvertibleNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-15 </startDate>
<endDate> 2022-07-15 </endDate>
</period>
</context>
<context id="icace22ebd6a7452a8bd96380d32fdb77_D20220715-20220715">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> nmtr:A2022ConvertibleNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-15 </startDate>
<endDate> 2022-07-15 </endDate>
</period>
</context>
<context id="i3bb3d70043cc48228471250dee324edd_I20230331">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001551986 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> srt:ScenarioForecastMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> nmtr:A2022ConvertibleNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<unit id="shares">
<measure> shares </measure>
</unit>
<unit id="usd">
<measure> iso4217:USD </measure>
</unit>
<unit id="usdPerShare">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="segment">
<measure> nmtr:segment </measure>
</unit>
<unit id="number">
<measure> pure </measure>
</unit>
<unit id="licenseagreement">
<measure> nmtr:licenseAgreement </measure>
</unit>
<unit id="equity-basedincentiveplan">
<measure> nmtr:equity-basedIncentivePlan </measure>
</unit>
<dei:AmendmentFlag contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80L2ZyYWc6MGE0ZWI2YzJiMmIwNGM5MTg2NGEzMzE4MWZiM2YzOTUvdGFibGU6YTgyY2Q2ZjZlZjMwNDNmNzk0MTU5YjM5ODA3OTkyMDIvdGFibGVyYW5nZTphODJjZDZmNmVmMzA0M2Y3OTQxNTliMzk4MDc5OTIwMl8yLTEtMS0xLTM0ODQ1_47cb2b34-8277-4f11-a5e4-c2f571467bbc"> false </dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80L2ZyYWc6MGE0ZWI2YzJiMmIwNGM5MTg2NGEzMzE4MWZiM2YzOTUvdGFibGU6YTgyY2Q2ZjZlZjMwNDNmNzk0MTU5YjM5ODA3OTkyMDIvdGFibGVyYW5nZTphODJjZDZmNmVmMzA0M2Y3OTQxNTliMzk4MDc5OTIwMl8zLTEtMS0xLTM0ODQ1_41cecc9e-f24d-4c09-8cb2-cbbd29b593f7"> 2022 </dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80L2ZyYWc6MGE0ZWI2YzJiMmIwNGM5MTg2NGEzMzE4MWZiM2YzOTUvdGFibGU6YTgyY2Q2ZjZlZjMwNDNmNzk0MTU5YjM5ODA3OTkyMDIvdGFibGVyYW5nZTphODJjZDZmNmVmMzA0M2Y3OTQxNTliMzk4MDc5OTIwMl80LTEtMS0xLTM0ODQ1_d6519715-03bc-4b8f-a420-cd5b28005982"> Q2 </dei:DocumentFiscalPeriodFocus>
<dei:EntityCentralIndexKey contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80L2ZyYWc6MGE0ZWI2YzJiMmIwNGM5MTg2NGEzMzE4MWZiM2YzOTUvdGFibGU6YTgyY2Q2ZjZlZjMwNDNmNzk0MTU5YjM5ODA3OTkyMDIvdGFibGVyYW5nZTphODJjZDZmNmVmMzA0M2Y3OTQxNTliMzk4MDc5OTIwMl82LTEtMS0xLTM0ODQ1_86617bd8-e822-4697-9cab-0b9d5a25fc02"> 0001551986 </dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80L2ZyYWc6MGE0ZWI2YzJiMmIwNGM5MTg2NGEzMzE4MWZiM2YzOTUvdGFibGU6YTgyY2Q2ZjZlZjMwNDNmNzk0MTU5YjM5ODA3OTkyMDIvdGFibGVyYW5nZTphODJjZDZmNmVmMzA0M2Y3OTQxNTliMzk4MDc5OTIwMl83LTEtMS0xLTM0ODQ1_aac1b5cd-45a5-4639-994f-0eca6115c383"> --12-31 </dei:CurrentFiscalYearEndDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="i2ca92cabf9614150b24cc79abfd6b15b_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzk0_3b893c6b-2915-41df-83f7-f458c0885f58"> P3Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<dei:DocumentType contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTM2_d8386172-ed21-45b8-9791-3d9f3262469e"> 10-Q </dei:DocumentType>
<dei:DocumentQuarterlyReport contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6MmE3NGIwMGMwMmJhNGE2ZTlhOWE0NjMwNWY5ZTcyYWYvdGFibGVyYW5nZToyYTc0YjAwYzAyYmE0YTZlOWE5YTQ2MzA1ZjllNzJhZl8wLTAtMS0xLTM0ODQ1_e714741e-88de-409f-b14c-a4a5a2bb127b"> true </dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8xMzc_a8af70ef-3d38-4a62-a76f-3cf583ef6c9c"> 2022-06-30 </dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6ZGE4NGNmNGI1M2EyNDkzNzlmNDliY2IzODRmMGUzNDQvdGFibGVyYW5nZTpkYTg0Y2Y0YjUzYTI0OTM3OWY0OWJjYjM4NGYwZTM0NF8wLTAtMS0xLTM0ODQ1_7f6aa44a-b6e5-47d6-b4f5-164f36b56e71"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTM3_da0b3e1c-3cd5-49b0-844d-f70c507b60cf"> 001-37797 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQ1_f4c0be55-1cf0-4681-b808-2615ec7b101e"> 9 METERS BIOPHARMA, INC. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6NGVmODYyMWEzMmJmNDhjYmE2NTllYmU3NTQwMmZiZWMvdGFibGVyYW5nZTo0ZWY4NjIxYTMyYmY0OGNiYTY1OWViZTc1NDAyZmJlY18wLTAtMS0xLTM0ODQ1_f8148216-7fe7-461d-8769-c2b406a7a4be"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6NGVmODYyMWEzMmJmNDhjYmE2NTllYmU3NTQwMmZiZWMvdGFibGVyYW5nZTo0ZWY4NjIxYTMyYmY0OGNiYTY1OWViZTc1NDAyZmJlY18wLTItMS0xLTM0ODQ1_c8f8a00b-abbd-41b0-818e-c6e28f20ba6d"> 27-3948465 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQ3_4cee4f16-5b00-45d6-a553-45a05c1e196d"> 8480 Honeycutt Road </dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQx_c2d0278e-22cb-4851-a166-e09c306ffa9a"> Suite 120 </dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTMz_d3f4fd7d-4571-4979-ae55-9a10eafb053a"> Raleigh </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQy_959198e3-ee82-4237-88b7-51897d4555fd"> NC </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8zOTI_6cdff4e5-f276-451b-8872-a4f05665ef93"> 27615 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF80NTk_f106b01b-9df3-4b1a-88b2-5df4c169228b"> 919 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTM1_e6e34d25-ee59-4262-b8c2-aa16d069875b"> 275-1933 </dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6MTczODBmNWQzMWM2NDExNDk4MjIzZWFjMDkxZjRmZWIvdGFibGVyYW5nZToxNzM4MGY1ZDMxYzY0MTE0OTgyMjNlYWMwOTFmNGZlYl8xLTAtMS0xLTM0ODQ1_62b6461f-b8f6-416d-bb79-6d5c0deb4888"> Common Stock $0.0001 Par Value </dei:Security12bTitle>
<dei:TradingSymbol contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6MTczODBmNWQzMWM2NDExNDk4MjIzZWFjMDkxZjRmZWIvdGFibGVyYW5nZToxNzM4MGY1ZDMxYzY0MTE0OTgyMjNlYWMwOTFmNGZlYl8xLTEtMS0xLTM0ODQ1_710b2c86-bc05-4f73-8584-6aac4487d2ff"> NMTR </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6MTczODBmNWQzMWM2NDExNDk4MjIzZWFjMDkxZjRmZWIvdGFibGVyYW5nZToxNzM4MGY1ZDMxYzY0MTE0OTgyMjNlYWMwOTFmNGZlYl8xLTItMS0xLTM0ODQ1_02cfcba0-f09c-4140-98c4-a594377c6b59"> NASDAQ </dei:SecurityExchangeName>
<dei:EntityCurrentReportingStatus contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQz_ee5e52bb-d0df-48d4-9114-00dea5b9d389"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTM5_47377408-cc82-49e9-a4ac-bcf9debeb960"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6ZTc5NTEzNDUwZjY2NGQ5MWIxMzNjNjAwNzFhYTVmOGMvdGFibGVyYW5nZTplNzk1MTM0NTBmNjY0ZDkxYjEzM2M2MDA3MWFhNWY4Y18xLTAtMS0xLTM0ODQ1_f1dae819-c228-41f6-8fef-83b665d01f95"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6ZTc5NTEzNDUwZjY2NGQ5MWIxMzNjNjAwNzFhYTVmOGMvdGFibGVyYW5nZTplNzk1MTM0NTBmNjY0ZDkxYjEzM2M2MDA3MWFhNWY4Y18xLTQtMS0xLTM0ODQ1_1ffa1358-c299-4a4e-81ac-a9246cc9b6d2"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGFibGU6ZTc5NTEzNDUwZjY2NGQ5MWIxMzNjNjAwNzFhYTVmOGMvdGFibGVyYW5nZTplNzk1MTM0NTBmNjY0ZDkxYjEzM2M2MDA3MWFhNWY4Y18yLTQtMS0xLTM0ODQ1_330318e7-597a-4576-b6da-d6d354641819"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMTQw_edce3642-a0cf-4562-9449-4a68bc03d0d1"> false </dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding contextRef="i561a0afe9ff04b959bba347becaf5714_I20220810" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xL2ZyYWc6ZjA2ZGUzNjdkODg4NGY3ZmE4ODcwZDU4YmQ2Nzk2ODAvdGV4dHJlZ2lvbjpmMDZkZTM2N2Q4ODg0ZjdmYTg4NzBkNThiZDY3OTY4MF8yMDU0_ea53a6f5-ae1a-404b-8e1a-80a986d136ee" unitRef="shares"> 259107380 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfNC0yLTEtMS0zNDg0NQ_cd721d26-7a6d-461b-a119-af49a99d1dba" unitRef="usd"> 29455788 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfNC00LTEtMS0zNDg0NQ_0f4c0061-5d3d-4ed2-9fd5-90a8e3ec2422" unitRef="usd"> 46993285 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfNy0yLTEtMS0zNDg0NQ_48889488-9687-4319-8f41-aa3870a3000d" unitRef="usd"> 1892310 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfNy00LTEtMS0zNDg0NQ_d840b5fd-1cd4-48a7-a337-e2a4308fd590" unitRef="usd"> 2991948 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfOS0yLTEtMS0zNDg0NQ_1b54a828-7b10-49a6-b6fd-b05ac545f63f" unitRef="usd"> 31348098 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfOS00LTEtMS0zNDg0NQ_d09edba7-9057-443c-adf1-f9fbbd45e251" unitRef="usd"> 49985233 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTEtMi0xLTEtMzQ4NDU_8c0636ca-732f-4fbd-b802-cee28177a0d5" unitRef="usd"> 14522 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTEtNC0xLTEtMzQ4NDU_e0e664b2-ca52-4b45-b64e-a388d0032bb4" unitRef="usd"> 16094 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTItMi0xLTEtMzQ4NDU_49318eb8-3c68-402a-980a-12298bccc3c0" unitRef="usd"> 140278 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTItNC0xLTEtMzQ4NDU_6ec52427-5de6-4a34-9a67-04011dc591cc" unitRef="usd"> 166618 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OtherAssetsNoncurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTMtMi0xLTEtMzQ4NDU_b49d4371-d521-4048-b15a-aef8c8f6f167" unitRef="usd"> 5580 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTMtNC0xLTEtMzQ4NDU_83f1ca98-848a-487b-b7bb-693394c9cea5" unitRef="usd"> 5580 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTQtMi0xLTEtMzQ4NDU_352ca279-e49b-444b-8215-3a9dbb908fbf" unitRef="usd"> 31508478 </us-gaap:Assets>
<us-gaap:Assets contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTQtNC0xLTEtMzQ4NDU_2ddd529d-f769-41ae-88bf-93a244747d76" unitRef="usd"> 50173525 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTktMi0xLTEtMzQ4NDU_81fc0c7d-c89d-4611-a534-d238eeb7150c" unitRef="usd"> 2326017 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMTktNC0xLTEtMzQ4NDU_ce1ea8dc-6e96-45ad-ad75-942ec19bc8a0" unitRef="usd"> 2434452 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjAtMi0xLTEtMzQ4NDU_6114c877-49ea-4bc1-abc7-7b4da742ff23" unitRef="usd"> 6955632 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjAtNC0xLTEtMzQ4NDU_907c2846-1811-4ee6-8b79-43d7e6d812e5" unitRef="usd"> 5967822 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjUtMi0xLTEtMzQ4NDU_a8c8b3c6-630c-4a70-b31a-a8f7f0c04e77" unitRef="usd"> 58167 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjUtNC0xLTEtMzQ4NDU_2af25436-7461-456e-bce5-1529fa8e8573" unitRef="usd"> 54796 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjYtMi0xLTEtMzQ4NDU_124bd85c-dbfc-4cc2-9ee3-43a4f1f35aa4" unitRef="usd"> 9339816 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjYtNC0xLTEtMzQ4NDU_869d2fc0-6d7b-4a2f-be7e-276de241c1ad" unitRef="usd"> 8457070 </us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjctMi0xLTEtMzQ4NDU_2e1b2a60-e761-437a-b97a-770c9d4afd66" unitRef="usd"> 83190 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjctNC0xLTEtMzQ4NDU_95b2a5ca-3dc7-427f-bb61-28f2e7bbf830" unitRef="usd"> 113142 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjgtMi0xLTEtMzQ4NDU_6e6b117e-0a11-4c8c-a11e-348e6fbf9084" unitRef="usd"> 9423006 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMjgtNC0xLTEtMzQ4NDU_cead1437-2a05-49b8-beaf-f61d51a270ef" unitRef="usd"> 8570212 </us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzAtMi0xLTEtMzQ4NDU_179af2bb-cfd5-49b8-8061-a22d025d8bed" unitRef="usd" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzAtNC0xLTEtMzQ4NDU_e5af8345-a1d3-4a8b-a06c-3d18d2c70229" unitRef="usd" xsi:nil="true"/>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl8yMA_8fc47dfd-a251-4319-ad18-32982e300bad" unitRef="usdPerShare"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl8yMA_d7516eba-9e29-4757-88dc-87b276c0f30e" unitRef="usdPerShare"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl80NA_225fbe6e-ebb5-4f28-872f-1bc11485d521" unitRef="shares"> 10000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl80NA_48317386-3321-465c-8245-1e78b8830646" unitRef="shares"> 10000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl82Ng_2479ef24-d018-456f-bb73-bfe000e7e09a" unitRef="shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl82Ng_bd5d7f9c-5db9-4a77-8bd3-5488dd1b421d" unitRef="shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl82Ng_dea71403-df80-42a3-b0fe-93e966b462a6" unitRef="shares"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjpmZDM2OTFiZjc4OTI0ZGNkYjFkODdlNjUxY2I3NzQ1Nl82Ng_fb0239dc-939f-474a-abf3-2ab6809bdd0e" unitRef="shares"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockValue contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtMi0xLTEtMzQ4NDU_922a7dc4-e53a-4915-ae12-031ad3e4bf05" unitRef="usd"> 0 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzMtNC0xLTEtMzQ4NDU_70001aac-d74f-4074-a5be-21cc6201fab2" unitRef="usd"> 0 </us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xNw_49b122ed-d90b-4884-a2b9-20454a26fe48" unitRef="usdPerShare"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xNw_8971c2f5-4cc1-479c-a5d0-be1e06bd64e9" unitRef="usdPerShare"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN180MQ_33ed45cf-3b62-4eac-a4a0-84b374078712" unitRef="shares"> 550000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN180MQ_7a249ed2-d062-4223-98f2-2d3d0ae8d792" unitRef="shares"> 550000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xMzI_194c0261-a83e-47f1-8f90-68dd548c0175" unitRef="shares"> 259107380 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xMzI_194d4f3f-d2b0-4e3e-89bd-f782a442095f" unitRef="shares"> 259107380 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xMDk5NTExNjI4MDI5_0a0fd7f9-657d-48df-91e6-6d77407ea93d" unitRef="shares"> 258235418 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMC0xLTEtMzQ4NDUvdGV4dHJlZ2lvbjo4MTk3Yjg2NTdkMmM0N2MyYWY4YzhiNzBiMTg3YjZkN18xMDk5NTExNjI4MDI5_45beccf6-86b7-45a3-9b64-f4056bc8f300" unitRef="shares"> 258235418 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockValue contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtMi0xLTEtMzQ4NDU_62f68208-7d8b-4437-8d67-736b7d607330" unitRef="usd"> 25911 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzQtNC0xLTEtMzQ4NDU_205fa3d1-f1c7-4ec8-a185-c21666f70c2f" unitRef="usd"> 25824 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzUtMi0xLTEtMzQ4NDU_3db83fa1-5735-4774-aa2e-89783841b6db" unitRef="usd"> 213382069 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzUtNC0xLTEtMzQ4NDU_fe713574-7e59-431a-a888-6bc1d9e3a3e2" unitRef="usd"> 210418156 </us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzYtMi0xLTEtMzQ4NDU_247d9aaf-65a0-4fa9-9c73-00f801cefcee" unitRef="usd"> -191322508 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzYtNC0xLTEtMzQ4NDU_df8376c0-bab2-41d7-8b13-ece8e516624e" unitRef="usd"> -168840667 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzctMi0xLTEtMzQ4NDU_6c8f0d7e-7866-4f0d-874c-897e8f147adf" unitRef="usd"> 22085472 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzctNC0xLTEtMzQ4NDU_a484dc7c-0900-442f-a64e-87e5dc9a0ddc" unitRef="usd"> 41603313 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzgtMi0xLTEtMzQ4NDU_ad171829-8307-4bad-8c6e-ab7e33ffb78d" unitRef="usd"> 31508478 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xNi9mcmFnOmEzMGUwMTJhNzRlNzRjNDA4ZjhkYzU1MjQyNTg3ZWQ3L3RhYmxlOmI4NWFiNTA1NGE4NDRlYWQ5NjhmZmZhMTU1YzhlOGNlL3RhYmxlcmFuZ2U6Yjg1YWI1MDU0YTg0NGVhZDk2OGZmZmExNTVjOGU4Y2VfMzgtNC0xLTEtMzQ4NDU_9b87a40b-5e67-4a24-a50c-a4561d6d9436" unitRef="usd"> 50173525 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMy0yLTEtMS0zNDg0NQ_5b62f169-d57a-45bf-9465-15f07f1afe4d" unitRef="usd"> 7546477 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMy00LTEtMS0zNDg0NQ_cfcb8037-318c-4b37-bf08-3023c6e666bd" unitRef="usd"> 5707290 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMy02LTEtMS0zNDg0NQ_adb40918-5601-4998-aa4c-283293b93e72" unitRef="usd"> 15914955 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMy04LTEtMS0zNDg0NQ_c50d0d9d-8329-425c-a4bd-0ff1d7941922" unitRef="usd"> 8897592 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:GeneralAndAdministrativeExpense contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNS0yLTEtMS0zNDg0NQ_f988b984-d835-488c-934e-b462c7e14216" unitRef="usd"> 3648944 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNS00LTEtMS0zNDg0NQ_0aff60fe-0f06-40e8-8d31-969bc8bce7cd" unitRef="usd"> 2551171 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNS02LTEtMS0zNDg0NQ_6a240490-595b-423b-aeea-394392269dc0" unitRef="usd"> 6644715 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNS04LTEtMS0zNDg0NQ_9596d93f-2487-4d21-8563-6e091506f549" unitRef="usd"> 4759971 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNy0yLTEtMS0zNDg0NQ_e39eae0a-70df-488c-bb6d-3ab7878b0e8f" unitRef="usd"> 11195421 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNy00LTEtMS0zNDg0NQ_81ed9531-3d83-4400-aced-fb48ec5bf8fb" unitRef="usd"> 8258461 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNy02LTEtMS0zNDg0NQ_0583e3de-511e-4ba7-95f3-51cce8fb6c65" unitRef="usd"> 22559670 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfNy04LTEtMS0zNDg0NQ_7ce1b03a-7317-4f0a-bb8e-2f366cbeafd5" unitRef="usd"> 13657563 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfOS0yLTEtMS0zNDg0NQ_bdf68811-3974-48f6-bf98-a4f271046bb7" unitRef="usd"> -11195421 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfOS00LTEtMS0zNDg0NQ_32b4c01f-e317-489d-8295-f9cb217092e9" unitRef="usd"> -8258461 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfOS02LTEtMS0zNDg0NQ_bc38bb17-a176-4af4-ae2e-595b512ffc45" unitRef="usd"> -22559670 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfOS04LTEtMS0zNDg0NQ_453889d7-d9bd-4775-859f-f757f1b5d61b" unitRef="usd"> -13657563 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeOther contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTItMi0xLTEtMzQ4NDU_fee8dcd6-2d64-4c0c-88a9-cbbc25629566" unitRef="usd"> 65319 </us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTItNC0xLTEtMzQ4NDU_8d12e6e1-a8af-4b6e-863e-4efb7faa3754" unitRef="usd"> 6505 </us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTItNi0xLTEtMzQ4NDU_9d70bbd2-81fc-4f23-8a7c-a8b7daee6a28" unitRef="usd"> 78133 </us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTItOC0xLTEtMzQ4NDU_3353df69-c0f1-40cb-bf1c-09915452a71b" unitRef="usd"> 11592 </us-gaap:InterestIncomeOther>
<us-gaap:InterestExpense contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTMtMi0xLTEtMzQ4NDU_e51c8882-c4b1-41a2-a723-0d8bd4e58f3d" unitRef="usd"> 0 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTMtNC0xLTEtMzQ4NDU_165eb4b2-4aa0-4c21-af42-bcfa61680ac1" unitRef="usd"> 1154 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTMtNi0xLTEtMzQ4NDU_5cd6d015-e615-48fe-96af-85e13cfa7757" unitRef="usd"> 304 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTMtOC0xLTEtMzQ4NDU_bf063f4a-d5a1-4e79-a815-c1246f3d9dc8" unitRef="usd"> 45218 </us-gaap:InterestExpense>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTUtMi0xLTEtMzQ4NDU_7b4642b9-e5ef-4f0a-9a43-363b7b6748f0" unitRef="usd"> 0 </us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTUtNC0xLTEtMzQ4NDU_0581829c-fbe5-4add-b142-fd9f92b7346b" unitRef="usd"> 0 </us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTUtNi0xLTEtMzQ4NDU_0175c981-99ea-485f-80d5-186e3cdb3e71" unitRef="usd"> 0 </us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTUtOC0xLTEtMzQ4NDU_12b2eaf3-f704-4266-9031-3b17853b72a4" unitRef="usd"> 7000 </us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTctMi0xLTEtMzQ4NDU_1d5e65fb-fcbe-49dc-8175-bf396e329e16" unitRef="usd"> 65319 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTctNC0xLTEtMzQ4NDU_e6f27776-c977-47e7-a447-a87d0c7a821c" unitRef="usd"> 5351 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTctNi0xLTEtMzQ4NDU_179714fe-c2e5-49ed-8649-908a73dead44" unitRef="usd"> 77829 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTctOC0xLTEtMzQ4NDU_49a01bd2-eed4-4a58-81fd-28956123fd58" unitRef="usd"> -26626 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTktMi0xLTEtMzQ4NDU_445a96cd-889d-4945-80c1-e594d09c6752" unitRef="usd"> -11130102 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTktNC0xLTEtMzQ4NDU_f7de46e4-e4dd-41ab-ae81-20eab6a02bea" unitRef="usd"> -8253110 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTktNi0xLTEtMzQ4NDU_2c3d613d-598a-46ef-9021-e69f74b4cd39" unitRef="usd"> -22481841 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMTktOC0xLTEtMzQ4NDU_398d10af-fb04-4fcd-a931-86438dbe6417" unitRef="usd"> -13684189 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjAtMi0xLTEtMzQ4NDU_e6b3c7e6-0d02-4212-8aca-76834a528502" unitRef="usd"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjAtNC0xLTEtMzQ4NDU_b242fb58-d2c3-4107-b332-985039b7f172" unitRef="usd"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjAtNi0xLTEtMzQ4NDU_32d7c941-4e6a-47fd-b48c-10e5bc47d0f0" unitRef="usd"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjAtOC0xLTEtMzQ4NDU_587e1a62-8159-4df9-b245-737180680327" unitRef="usd"> 0 </us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjItMi0xLTEtMzQ4NDU_a692fd84-9377-4a7d-b2b2-968a3e485a7d" unitRef="usd"> -11130102 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjItNC0xLTEtMzQ4NDU_743d3363-2e5d-494b-ae26-606e9ae5f0bc" unitRef="usd"> -8253110 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjItNi0xLTEtMzQ4NDU_033c673c-a20a-45eb-ae79-b67699d88a57" unitRef="usd"> -22481841 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjItOC0xLTEtMzQ4NDU_273add7d-3993-4cd2-a856-a2b7025f56ea" unitRef="usd"> -13684189 </us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareDiluted contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtMi0xLTEtMzQ4NDU_1e12df80-1bef-4eae-93a2-7ac3bb4a0010" unitRef="usdPerShare"> -0.04 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtMi0xLTEtMzQ4NDU_e84aa723-0003-4e0a-860d-b2a1b79584eb" unitRef="usdPerShare"> -0.04 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtNC0xLTEtMzQ4NDU_ac9815e0-c3bd-4dfe-86ca-89376424fbf6" unitRef="usdPerShare"> -0.03 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtNC0xLTEtMzQ4NDU_e51b98ec-0f6c-4691-afa9-7c7b3bb0bc71" unitRef="usdPerShare"> -0.03 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtNi0xLTEtMzQ4NDU_214c2f47-9fcc-4679-b4f8-25672dc16abc" unitRef="usdPerShare"> -0.09 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtNi0xLTEtMzQ4NDU_eff380f1-dcf8-4795-afdd-bc10af911d92" unitRef="usdPerShare"> -0.09 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtOC0xLTEtMzQ4NDU_1e452846-b28a-4a6f-925a-cce23cb920fe" unitRef="usdPerShare"> -0.06 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjQtOC0xLTEtMzQ4NDU_8a5345f4-f174-4e13-8ac5-43049ba77a14" unitRef="usdPerShare"> -0.06 </us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtMi0xLTEtMzQ4NDU_234802b2-a9e3-45fb-8c21-622e6ebaffe3" unitRef="shares"> 259001978 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtMi0xLTEtMzQ4NDU_3fd72edd-4565-4307-8990-766df0bc8d83" unitRef="shares"> 259001978 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtNC0xLTEtMzQ4NDU_42617668-a28f-4e14-842d-936506cc5409" unitRef="shares"> 249552315 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtNC0xLTEtMzQ4NDU_72bd4b76-79a9-4950-b2ec-5cc49ef972d0" unitRef="shares"> 249552315 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtNi0xLTEtMzQ4NDU_90623652-72e2-4020-8c65-9a3ec6a7c2e7" unitRef="shares"> 258620816 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtNi0xLTEtMzQ4NDU_e532ae3e-c2aa-4f65-993c-34e5525b2cc3" unitRef="shares"> 258620816 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtOC0xLTEtMzQ4NDU_be361f34-ba6f-4170-90ad-f47829c6d994" unitRef="shares"> 230522313 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8xOS9mcmFnOjgwZWU5ZDA2ZjQ1YjRkZWNhZjA1ODE5OGNmMjM2NjVlL3RhYmxlOjMwNGNjNDhjZTQwYTQ2NTZiZTQzY2EwYTM0Mzk4NjJlL3RhYmxlcmFuZ2U6MzA0Y2M0OGNlNDBhNDY1NmJlNDNjYTBhMzQzOTg2MmVfMjYtOC0xLTEtMzQ4NDU_c40c994a-4b7f-4188-8191-4411ee6c975a" unitRef="shares"> 230522313 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="i1ad30f72f6084432a7afa6db908bc3d8_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMi00LTEtMS0zNDg0NQ_18971542-7c84-4489-88c7-fe0cde9ca319" unitRef="shares"> 258235418 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="i1ad30f72f6084432a7afa6db908bc3d8_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMi01LTEtMS0zNDg0NQ_07baba4d-9ec8-4dc6-8281-f9e20107dcbf" unitRef="usd"> 25824 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="ib75b7f8361824b3299a692bbea1076cc_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMi02LTEtMS0zNDg0NQ_1c6c581c-09f5-4f70-bd00-95116b348fc9" unitRef="usd"> 210418156 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i2f260a3791444489a23f6305d3e0a348_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMi03LTEtMS0zNDg0NQ_22fdb38b-7c75-4576-92ea-1ad0ed4dc93a" unitRef="usd"> -168840667 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMi04LTEtMS0zNDg0NQ_44b594f3-62db-492a-90e5-9d828f1c7107" unitRef="usd"> 41603313 </us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i829c83d880ea4c4db4fdd42f05907bc1_D20220101-20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfNC02LTEtMS0zNDg0NQ_4667d2ef-af8e-4f80-98c5-3ecd08501c98" unitRef="usd"> 690000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i0077bbf3925941e7a7abaa0706eed2f2_D20220101-20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfNC04LTEtMS0zNDg0NQ_b6539cd3-c361-4ca9-a7e0-1fee724b3d42" unitRef="usd"> 690000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:NetIncomeLoss contextRef="i5bcb9dd2dc984102865532e65f8d2876_D20220101-20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOC03LTEtMS0zNDg0NQ_d75854cd-4685-4bf6-849a-48eb7569fd38" unitRef="usd"> -11351739 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i0077bbf3925941e7a7abaa0706eed2f2_D20220101-20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOC04LTEtMS0zNDg0NQ_a0ce0c6b-8ba3-40cf-8181-73f2ff88fabc" unitRef="usd"> -11351739 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="i6971608db72d415aa515b8bfffca0cd6_I20220331" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOS00LTEtMS0zNDg0NQ_a0d0b39b-817c-458d-b577-d85390c80638" unitRef="shares"> 258235418 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="i6971608db72d415aa515b8bfffca0cd6_I20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOS01LTEtMS0zNDg0NQ_6b3ed4fb-75b0-4b4d-ab50-e67cb3016564" unitRef="usd"> 25824 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i43011da2aead48bd9f4cf099f8db4d66_I20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOS02LTEtMS0zNDg0NQ_3a96b3b4-3144-4afe-bb3e-a29c79996ef6" unitRef="usd"> 211108156 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i678eaa6a68af4f40a0438b9e84c52468_I20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOS03LTEtMS0zNDg0NQ_a7d0b504-c8f4-4b91-9806-970bb0b1fdec" unitRef="usd"> -180192406 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i60d9ddd634b64bfd83b0ad11334421d1_I20220331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfOS04LTEtMS0zNDg0NQ_2962effd-f35d-4aa2-b13f-3024df939004" unitRef="usd"> 30941574 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="i2d01ef06217f49e18732c9bd0a775710_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTAtNC0xLTEtMzQ4NDU_6e8de1b7-838a-4be6-87bb-883776961d57" unitRef="shares"> 871962 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="i2d01ef06217f49e18732c9bd0a775710_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTAtNS0xLTEtMzQ4NDU_972c4817-49fc-4108-8698-81172250c84f" unitRef="usd"> 87 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="ib47d3e0986df43958c3def03d1db4cea_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTAtNi0xLTEtMzQ4NDU_a1f0727f-89ec-4412-b12c-7458eb3f2458" unitRef="usd"> 499913 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTAtOC0xLTEtMzQ4NDU_4cbbab68-a111-4ddd-94e3-8fcd3488a870" unitRef="usd"> 500000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="ib47d3e0986df43958c3def03d1db4cea_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTMtNi0xLTEtMzQ4NDU_eea9d36c-f4aa-4cdc-a200-99e80efb298f" unitRef="usd"> 1774000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMTMtOC0xLTEtMzQ4NDU_359c9c53-7bd1-4ef9-b79a-b64923a2557e" unitRef="usd"> 1774000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:NetIncomeLoss contextRef="i71b778589cff47a897071b0ad0e2e936_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMjAtNy0xLTEtMzQ4NDU_546036fd-5990-4942-81d2-64e275bf55b0" unitRef="usd"> -11130102 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMjAtOC0xLTEtMzQ4NDU_53bb85b6-79a1-4223-983d-22b219229c9d" unitRef="usd"> -11130102 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="i706b2ae4393245d9b60d7122688533af_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMzAtNC0xLTEtMzQ4NDU_e87f14bd-c1d4-418f-b8a3-6358cac45af2" unitRef="shares"> 259107380 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="i706b2ae4393245d9b60d7122688533af_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMzAtNS0xLTEtMzQ4NDU_205fd060-1c21-4a57-9f1b-d68c386ebefe" unitRef="usd"> 25911 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i4662a20e990b4fcab6b236f1b3363200_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMzAtNi0xLTEtMzQ4NDU_90769b83-6a9c-4de6-a6be-f174e11b5e1c" unitRef="usd"> 213382069 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="ifb788d4de59e4f3daea12d3337766033_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMzAtNy0xLTEtMzQ4NDU_6bb357a2-d8b4-4f02-987b-82e66bbc9330" unitRef="usd"> -191322508 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmY5Yzg3MDQ4ZDVjOTQ4ZDJhOTAzNDBkMzYxYjQ1YWQzL3RhYmxlcmFuZ2U6ZjljODcwNDhkNWM5NDhkMmE5MDM0MGQzNjFiNDVhZDNfMzAtOC0xLTEtMzQ4NDU_196183bb-03e6-414b-9384-349660282670" unitRef="usd"> 22085472 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="iaee7d2c90d4f47df971bd2f0bd6f72f4_I20201231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMi02LTEtMS0zNDg0NQ_398af49f-b844-41eb-8f4b-f0f5662dc5f8" unitRef="shares"> 204629064 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="iaee7d2c90d4f47df971bd2f0bd6f72f4_I20201231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMi04LTEtMS0zNDg0NQ_3bc8673e-9fa3-4da5-b7a2-40485c4d239a" unitRef="usd"> 20463 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i9c5baf0d76cb47d98dd9a47ab7b1a659_I20201231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMi0xMC0xLTEtMzQ4NDU_b156a29b-8119-4d2b-95d1-e1b4c2ac930b" unitRef="usd"> 164182917 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="id6ec8051cf8040338440d6ed67131ac7_I20201231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMi0xMi0xLTEtMzQ4NDU_93b82dbb-42c1-4bfe-8054-fd55f2713ef0" unitRef="usd"> -132061267 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i1273166b31f14a28bb435260be02d93e_I20201231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMi0xNC0xLTEtMzQ4NDU_f63f3535-e630-43df-85ec-e5d99d479134" unitRef="usd"> 32142113 </us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i8b758bf8f26f4f28ba9085b071ae03fc_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMy0xMC0xLTEtMzQ4NDU_623ce496-6261-418c-94c6-be8a1a22df70" unitRef="usd"> 422000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i269aa8d981fc4d1d9e7e8c7c29b4d1da_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMy0xNC0xLTEtMzQ4NDU_e614e091-64ad-45e9-ad59-eb21065ee19d" unitRef="usd"> 422000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<nmtr:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="i397f258f2fcf47f086d0c29d51188dfb_D20210101-20210331" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNC02LTEtMS0zNDg0NQ_c9f60cf9-48e0-4bb2-b060-9b5c254b8f4d" unitRef="shares"> 11634151 </nmtr:StockIssuedDuringPeriodSharesWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="i397f258f2fcf47f086d0c29d51188dfb_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNC04LTEtMS0zNDg0NQ_ebad673d-d9b4-446d-a318-63d63f82a6f6" unitRef="usd"> 1163 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="i8b758bf8f26f4f28ba9085b071ae03fc_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNC0xMC0xLTEtMzQ4NDU_da1eadaf-b0a4-4822-8ded-77d0aa80b24b" unitRef="usd"> 6855865 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="i269aa8d981fc4d1d9e7e8c7c29b4d1da_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNC0xNC0xLTEtMzQ4NDU_2109b838-69c2-49e0-a8bc-62b66d3ced8d" unitRef="usd"> 6857028 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i397f258f2fcf47f086d0c29d51188dfb_D20210101-20210331" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNS02LTEtMS0zNDg0NQ_2875a6d0-7635-4923-88f3-31b1532781d6" unitRef="shares"> 61681 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="i397f258f2fcf47f086d0c29d51188dfb_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNS04LTEtMS0zNDg0NQ_daf23fac-bf36-4750-b130-094c12d35c79" unitRef="usd"> 6 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="i8b758bf8f26f4f28ba9085b071ae03fc_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNS0xMC0xLTEtMzQ4NDU_3437803a-b3e4-4904-b66c-494fbc4ae0a8" unitRef="usd"> 75897 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="i269aa8d981fc4d1d9e7e8c7c29b4d1da_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfNS0xNC0xLTEtMzQ4NDU_71cfbbf5-3c12-49ba-b440-d4259c4f1e47" unitRef="usd"> 75903 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:NetIncomeLoss contextRef="id479c133b0a149fd8878c46299c01b1b_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOC0xMi0xLTEtMzQ4NDU_95c13e87-3b13-42c1-b9c3-42bf4cb4dad8" unitRef="usd"> -5431079 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i269aa8d981fc4d1d9e7e8c7c29b4d1da_D20210101-20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOC0xNC0xLTEtMzQ4NDU_a05dddaf-c324-49c4-9105-9422c2908f7e" unitRef="usd"> -5431079 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="id39b8404dbd74c75a23046d8777ebe66_I20210331" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOS02LTEtMS0zNDg0NQ_136ee01f-ee6a-4c50-a73a-009c798e436b" unitRef="shares"> 216324896 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="id39b8404dbd74c75a23046d8777ebe66_I20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOS04LTEtMS0zNDg0NQ_65ee9911-5285-4d77-aecf-0f702d19e5dc" unitRef="usd"> 21632 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="if600423d126e45dcb47c204347979d89_I20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOS0xMC0xLTEtMzQ4NDU_d51aca74-f6b6-48a5-8757-4ad2a9dbf640" unitRef="usd"> 171536679 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="ib38b36d8ace346ceb16938d0800c668b_I20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOS0xMi0xLTEtMzQ4NDU_bd1b8059-a563-4f61-b69b-e472c6f25973" unitRef="usd"> -137492346 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i67bc54fcbc2e46ddadff383f2f0c5541_I20210331" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfOS0xNC0xLTEtMzQ4NDU_2507715a-604a-485d-b9dd-7a79075ca052" unitRef="usd"> 34065965 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTAtNi0xLTEtMzQ4NDU_ffaff6ea-e339-4b18-8d73-264633f36afd" unitRef="shares"> 34500000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTAtOC0xLTEtMzQ4NDU_02d2664f-7b5b-4c2f-b3e7-689752c128f8" unitRef="usd"> 3450 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTAtMTAtMS0xLTM0ODQ1_e6ad3a07-2914-4efe-82e9-cce36e277bb9" unitRef="usd"> 34496550 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTAtMTQtMS0xLTM0ODQ1_3ec0a014-5e8a-4615-9546-bd4b59e8e42b" unitRef="usd"> 34500000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTEtMTAtMS0xLTM0ODQ1_8478981b-a590-4810-a87d-489fc5dd78c8" unitRef="usd"> 2901123 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTEtMTQtMS0xLTM0ODQ1_88060375-a5b4-4b8e-9bce-410c213dfa3b" unitRef="usd"> 2901123 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTMtMTAtMS0xLTM0ODQ1_d9304623-a9d9-48ea-8a04-81b7be20ee7f" unitRef="usd"> 937000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTMtMTQtMS0xLTM0ODQ1_74b373c9-711e-4d81-8a45-78b19337f1d9" unitRef="usd"> 937000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<nmtr:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtNi0xLTEtMzQ4NDU_82ad6ab7-a4fa-42cd-be9a-cfc60e1dbe50" unitRef="shares"> 1134100 </nmtr:StockIssuedDuringPeriodSharesWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtOC0xLTEtMzQ4NDU_bec6b2df-2632-4542-a9bc-0650f367cc49" unitRef="usd"> 114 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtMTAtMS0xLTM0ODQ1_a74d893a-1de7-4d2e-95b6-dfabb40df139" unitRef="usd"> 668325 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtMTQtMS0xLTM0ODQ1_eb5f0dff-dc3c-4373-b98c-01a3eb090d64" unitRef="usd"> 668439 </nmtr:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtNi0xLTEtMzgzOTU_dd26dea6-79d7-4513-a21d-c0f31c6e9385" unitRef="shares"> 276944 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="ied341f12ff6746e7bf53acc651f7dadb_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTQtOC0xLTEtMzgzODY_f0a6ee56-173a-4347-90ae-927a4cbf6b1f" unitRef="usd"> 28 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="i3c230bc3667745dc835476e5447d21bd_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTUtMTAtMS0xLTM0ODQ1_5bc2bf7f-24fb-46d3-837c-d370917a19ce" unitRef="usd"> 120711 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMTUtMTQtMS0xLTM0ODQ1_55bc0d2d-a097-41c9-8f85-26dbf64fdbe6" unitRef="usd"> 120739 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:NetIncomeLoss contextRef="i928878b584244700a596276e856c782a_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjAtMTItMS0xLTM0ODQ1_74f0a6a2-b364-4089-b8bd-84564fe49046" unitRef="usd"> -8253110 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjAtMTQtMS0xLTM0ODQ1_4b9a156b-f8fc-45d3-a6ed-a187a0364b87" unitRef="usd"> -8253110 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="i4b42a002164b43bea0d7f189c71843c3_I20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjktNi0xLTEtMzQ4NDU_2e1e876a-eeff-460a-bf24-0d38e7e76e14" unitRef="shares"> 252235940 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="i4b42a002164b43bea0d7f189c71843c3_I20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjktOC0xLTEtMzQ4NDU_aa48bf48-61b8-4fcc-96dd-f27f58b8ba47" unitRef="usd"> 25224 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="id794d4ca86224b4583b0ccd00d7f8b85_I20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjktMTAtMS0xLTM0ODQ1_a2e4c74e-911c-42ae-87d2-14302332782d" unitRef="usd"> 204858142 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="iefc3653a940b4b30ac2f0b2d0185223e_I20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjktMTItMS0xLTM0ODQ1_29b8ad20-e5a9-4fd5-83e6-bda957bae8b5" unitRef="usd"> -145745456 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yMi9mcmFnOmFjNzlmZDI3ZGEzNTQ0ZGU5MTExMmUwNWYzYzRlMzVhL3RhYmxlOmNiNDhhZGQ3YTgwYTQ3NGI4YjU5NjIwMTRiNjcxYTc0L3RhYmxlcmFuZ2U6Y2I0OGFkZDdhODBhNDc0YjhiNTk2MjAxNGI2NzFhNzRfMjktMTQtMS0xLTM0ODQ1_35118113-33a9-43d7-aaba-08c815ce71a4" unitRef="usd"> 59137910 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMy0yLTEtMS0zNDg0NQ_18ba9b17-3b21-4c57-b8ed-8d3399448c01" unitRef="usd"> -22481841 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMy00LTEtMS0zNDg0NQ_62c7ec78-0269-444d-b936-bfccbf56a659" unitRef="usd"> -13684189 </us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNS0yLTEtMS0zNDg0NQ_86c38f5c-6afb-4089-96c9-c675bb9d02da" unitRef="usd"> 2464000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNS00LTEtMS0zNDg0NQ_99d6a8b9-f7dd-4c2c-a3b2-ac1b2a3db7c7" unitRef="usd"> 1359000 </us-gaap:ShareBasedCompensation>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfOC0yLTEtMS0zNDg0NQ_72e4bf13-d0ea-43f8-9ceb-a2af5da9d1f3" unitRef="usd"> 0 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfOC00LTEtMS0zNDg0NQ_79975717-1533-4772-918d-281996e53e0e" unitRef="usd"> 43983 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:Depreciation contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTAtMi0xLTEtMzQ4NDU_4fe70353-87f0-4179-a965-4c9d162a37b4" unitRef="usd"> 4414 </us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTAtNC0xLTEtMzQ4NDU_b2da9350-b879-4c81-9801-35748b284b85" unitRef="usd"> 3331 </us-gaap:Depreciation>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTItMi0xLTEtMzQ4NDU_10fa03be-235d-4a3c-a535-2402d64d9734" unitRef="usd"> 0 </us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTItNC0xLTEtMzQ4NDU_8c16a5d9-a72a-41f8-92b5-e557050c392f" unitRef="usd"> -7000 </us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<nmtr:NonCashMilestoneFees contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTQtMi0xLTEtMzQ4NDU_29b4f90e-dd7d-455e-93e5-0d2fc72dc6ed" unitRef="usd"> 500000 </nmtr:NonCashMilestoneFees>
<nmtr:NonCashMilestoneFees contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTQtNC0xLTEtMzQ4NDU_33abdbca-371b-4a76-a14a-8578520f4884" unitRef="usd"> 0 </nmtr:NonCashMilestoneFees>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTktMi0xLTEtMzQ4NDU_8f508f33-0d65-4a01-bd67-1a9a03b441d0" unitRef="usd"> -1099638 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMTktNC0xLTEtMzQ4NDU_04f16e4a-6ac3-49e9-95f4-5be54880eb2d" unitRef="usd"> 683640 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjAtMi0xLTEtMzQ4NDU_bd4dab31-e1c4-4d0b-b87f-385a64535c53" unitRef="usd"> -108435 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjAtNC0xLTEtMzQ4NDU_c2893610-f900-4a07-9c83-c93235c6fdb2" unitRef="usd"> -102373 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjEtMi0xLTEtMzQ4NDU_8ee7ee6c-288e-4b60-b007-bb46f7470c17" unitRef="usd"> 987569 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjEtNC0xLTEtMzQ4NDU_e1df85e1-56a2-4404-96a9-b0ee7bb5e679" unitRef="usd"> -262445 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjItMi0xLTEtMzQ4NDU_b227eb14-9390-4092-adec-fdaf380d5733" unitRef="usd"> 0 </us-gaap:IncreaseDecreaseInInterestPayableNet>
<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjItNC0xLTEtMzQ4NDU_f5036032-e406-4751-8862-f1ae15c4ce76" unitRef="usd"> -488 </us-gaap:IncreaseDecreaseInInterestPayableNet>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjMtMi0xLTEtMzQ4NDU_9e25d1fd-69f8-41e9-ac4b-fd89585d801b" unitRef="usd"> -17534655 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjMtNC0xLTEtMzQ4NDU_64d397f8-0a0d-44d0-a800-2e52c1a5700d" unitRef="usd"> -13333821 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjUtMi0xLTEtMzQ4NDU_0e7424cc-8cfd-42b3-a803-98d0d1b2599a" unitRef="usd"> 2842 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjUtNC0xLTEtMzQ4NDU_e6e49c35-acd0-46b9-a817-d6862b446b66" unitRef="usd"> 6892 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjgtMi0xLTEtMzQ4NDU_c51e6e85-101f-4d60-b324-32ceeb33887d" unitRef="usd"> -2842 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMjgtNC0xLTEtMzQ4NDU_fcf17c8a-6bc7-4845-a276-957202594d1c" unitRef="usd"> -6892 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfDebt contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzEtMi0xLTEtMzQ4NDU_dd123e8a-abef-4558-af42-b18cca1ce5a2" unitRef="usd"> 0 </us-gaap:RepaymentsOfDebt>
<us-gaap:RepaymentsOfDebt contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzEtNC0xLTEtMzQ4NDU_a497bff2-3774-4644-9c32-7500624a6b49" unitRef="usd"> 58199 </us-gaap:RepaymentsOfDebt>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzMtMi0xLTEtMzQ4NDU_331c9ebb-b83e-4c91-b25e-350d6dfc49c2" unitRef="usd"> 0 </us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzMtNC0xLTEtMzQ4NDU_b3b29def-abdd-4715-b858-73891e4d27d4" unitRef="usd"> 196642 </us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzQtMi0xLTEtMzQ4NDU_87c5b6b2-f9fb-4b60-ab89-6c6a9224031d" unitRef="usd"> 0 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzQtNC0xLTEtMzQ4NDU_589ff314-4383-486b-9d98-343df23d4bdc" unitRef="usd"> 34500000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzYtMi0xLTEtMzQ4NDU_14a256bf-1422-408e-8dd3-24c70a5c2e57" unitRef="usd"> 0 </us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzYtNC0xLTEtMzQ4NDU_6bfe0346-d6cc-4baf-84f1-cd56d72f7b52" unitRef="usd"> 2651123 </us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:ProceedsFromWarrantExercises contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzctMi0xLTEtMzQ4NDU_ae2a8c7c-3162-4a6c-8c02-24288a209d4e" unitRef="usd"> 0 </us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzctNC0xLTEtMzQ4NDU_111462ef-95e2-4f00-b3ef-4d4cf87494eb" unitRef="usd"> 7525467 </us-gaap:ProceedsFromWarrantExercises>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzgtMi0xLTEtMzQ4NDU_17994896-a8bc-4abc-8100-bd4f3d00e40d" unitRef="usd"> 0 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzgtNC0xLTEtMzQ4NDU_a3e65b5f-8977-47f3-b077-3b6526bd6fc6" unitRef="usd"> 39512787 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzktMi0xLTEtMzQ4NDU_4f797a63-3c28-4226-be42-613b72fdfef1" unitRef="usd"> -17537497 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfMzktNC0xLTEtMzQ4NDU_3d98187e-f1d6-4df9-bef9-9448bd231234" unitRef="usd"> 26172074 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDAtMi0xLTEtMzQ4NDU_19b35ede-20c4-4872-afb1-d68af884540e" unitRef="usd"> 46993285 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i1273166b31f14a28bb435260be02d93e_I20201231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDAtNC0xLTEtMzQ4NDU_23c62531-8097-4e7d-a6d6-98cc748e02eb" unitRef="usd"> 37851388 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDEtMi0xLTEtMzQ4NDU_b7cdb793-69cb-4345-91d4-6a2f85c20ebf" unitRef="usd"> 29455788 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDEtNC0xLTEtMzQ4NDU_522af172-b71c-4fd0-afc9-71bf8624e762" unitRef="usd"> 64023462 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:InterestPaidNet contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDQtMi0xLTEtMzQ4NDU_f1c7176c-9ef1-44a4-958f-5cb65720f517" unitRef="usd"> 0 </us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNDQtNC0xLTEtMzQ4NDU_7a8b45a7-2bab-42ca-bb36-bae617a220dc" unitRef="usd"> 569 </us-gaap:InterestPaidNet>
<nmtr:NoncashAdditionOfStockOfferingCosts contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNTItMi0xLTEtMzQ4NDU_3bc1fce0-54e9-4739-aee7-0f69075f8d5c" unitRef="usd"> 0 </nmtr:NoncashAdditionOfStockOfferingCosts>
<nmtr:NoncashAdditionOfStockOfferingCosts contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8yNS9mcmFnOjdkMjg4MWVmMTY4ZjQ0NmNhYTQzMDZiMTNjNzA4YWQ0L3RhYmxlOjIwZmI0MGEwZWQ4OTRlNmI4MDY3NWFiMzQ3NDJiMzFiL3RhYmxlcmFuZ2U6MjBmYjQwYTBlZDg5NGU2YjgwNjc1YWIzNDc0MmIzMWJfNTItNC0xLTEtMzQ4NDU_e9e7d15b-c16d-4ece-b986-7bd890e0346c" unitRef="usd"> 250000 </nmtr:NoncashAdditionOfStockOfferingCosts>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5ODk_bae2435a-3a2b-4d6e-843f-192cf79e8656">
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Description</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 Meters Biopharma, Inc. (the “Company”) is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company’s pipeline includes drug candidates vurolenatide, a proprietary long-acting GLP-1 agonist for short bowel syndrome (“SBS”), an orphan designated disease, larazotide, a tight junction regulator being evaluated for multi-system inflammatory syndrome in children (“MIS-C”), and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. These financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary for a fair statement of the balance sheets, operating results, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other future period. Certain information and footnote disclosure normally included in the annual financial statements prepared in accordance with U.S. GAAP have been omitted in accordance with the SEC’s rules and regulations for interim reporting. The Company’s financial position, results of operations and cash flows are presented in U.S. Dollars. These financial statements and related notes should be read in conjunction with the audited financial statements and related notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 23, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below under the section entitled “Recently Issued Accounting Standards—Accounting Pronouncements Adopted,” there have been no material changes to the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared to the significant accounting policies disclosed in Note 1 of the Company’s financial statements for the years ended December 31, 2021 and 2020 included in the Company’s Annual Report on Form 10-K. However, the following accounting policies are the most critical in fully understanding the Company’s financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Filing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 2, 2020, the Company filed a shelf registration statement that was declared effective on October 9, 2020 (the “Current Registration Statement”). Pursuant to the Current Registration Statement, the Company may from time to time offer, issue and sell in one or more offerings of various types of securities up to an aggregate dollar amount of $200 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2020, the Company filed a prospectus supplement and associated sales agreement (the “Sales Agreement”) related to an “at-the-market” offering pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through Truist Securities, Inc. (previously SunTrust Robinson Humphrey), or Truist, as sales agent, for general corporate purposes (the “2020 ATM”). In October 2020, the Company entered into an amendment to the Sales Agreement to reflect the termination of the prior registration statement and effectiveness of the Current Registration Statement. During the three and six months ended June 30, 2022 and 2021, the Company did not sell any shares under the Sales Agreement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2021 Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets, Inc., William Blair & Company, L.L.C. and Truist, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the public offering of 30,000,000 shares of the Company’s common stock at a price of $1.00 per share, less underwriting discounts and commissions (the “April 2021 Offering”). Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 4,500,000 shares of common stock at the same price, which the Underwriters exercised in full on March 31, 2021. On April 5, 2021, upon closing of the April 2021 Offering, the Company received net proceeds of approximately $31.5 million after deducting underwriting discounts and commissions and offering expenses. The shares issued in the April 2021 Offering were registered and sold under the Current Registration Statement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the shares of common stock issued in the April 2021 Offering, the Company’s Chief Executive Officer, then-current Chief Financial Officer and Chairman of the Board of Directors purchased an aggregate of 450,000 shares at the public offering price and on the same terms as the other purchasers in the offering. The underwriters received the same underwriting discount on the shares purchased by the Company’s Chief Executive Officer, then-current Chief Financial Officer and Chairman of the Board of Directors. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces risks, including those associated with biopharmaceutical companies whose products are in various stages of development. These risks include, among others, risks related to the Company’s ability to successfully implement its strategic plans; uncertainties associated with the clinical development and regulatory approval of product candidates, including reliance on blinded data; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom, including the Company’s reliance on its lead product candidate; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on the Company’s operations, enrollment in and timing of clinical trials; risks related to leveraging the Company by borrowing money under the debt facility and compliance with its terms; risk of delisting from Nasdaq; reliance on collaborators; reliance on research and development partner; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of COVID-19 began in December 2019 and on March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic and its resurgences are affecting the United States and global economies and may continue to affect the Company’s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company’s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration (the “FDA”) and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company’s product candidates. The COVID-19 pandemic has led to slower enrollment in the Company’s clinical trials and could continue to impact enrollment directly or indirectly. Patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency. Such facilities and offices may also be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not be available, in whole or in part, for clinical trial services related to the Company’s product candidates. New and potentially more contagious variants, such as the Omicron variant, could further affect the impact that the COVID-19 pandemic has on the Company’s operations. The impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital in the future, which could negatively impact the Company’s long-term liquidity. The Company’s assessment of the impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three and six months ended June 30, 2022. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs periodic expenses such as research and development, licensing fees, salaries and benefits, and professional fees. The Company is required to estimate its expenses resulting from obligations under contracts with clinical research organizations, vendors and consulting agreements that have been incurred by the Company prior to being invoiced. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses as of each balance sheet date based on facts and circumstances known at that time.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.184%"><tr><td style="width:1.0%"/><td style="width:56.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, <br/>2022<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,439,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative and Hedging, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the condensed consolidated balance sheet at fair value. There were no outstanding derivative liabilities as of June 30, 2022 or December 31, 2021. Historically, the Company’s derivative financial instruments consisted of embedded options in the Company’s convertible notes, and it expects to have similar accounting treatment of debt under the securities purchase agreement and related convertible note described in Note 10—Subsequent Events. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred to further the Company’s research and development activities and include salaries and related employee benefits, manufacturing of pharmaceutical active ingredients and drug products, costs associated with clinical trials, nonclinical activities, regulatory activities, research-related overhead expenses and fees paid to expert consultants, external service providers and contract research organizations which conduct certain research and development activities on behalf of the Company. Costs incurred in the research and development of products are charged to research and development expense as incurred.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided by vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. The estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Although the Company does not expect its estimates to be materially different from amounts incurred, the Company’s estimates and assumptions for clinical trial costs could differ significantly from actual costs incurred, which could result in increases or decreases in research and development expenses in future periods when actual results are known.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the goods have been received or when the activity is performed, rather than when payment is made.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-process Research and Development </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired, and may in the future acquire, rights to develop and commercialize new drug candidates and/or other in-process research and development assets. The up-front acquisition payments, as well as future milestone payments that are deemed probable to achieve and do not meet the definition of a derivative, are expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and, absent obtaining such approval, have no alternative future use.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense for grants of stock options based on the grant-date fair value of those awards using the Black-Scholes option-pricing model. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service period for awards with time-based vesting. For awards with performance conditions, compensation cost is recognized from the time achievement of the performance criteria is probable over the expected term. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Under the Black-Scholes option-pricing model, fair value is calculated based on assumptions with respect to:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected dividend yield.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected stock-price volatility.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to limited trading history as a public company, the expected volatility is derived from the average historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term. In evaluating comparable companies, the Company considers factors such as industry, stage of life cycle, financial leverage, size and risk profile. </span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Risk-free interest rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited history of stock option exercises, the Company estimates the expected term of employee stock options with service conditions based on the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options. Pursuant to Accounting Standards Update (“ASU”) 2018-07, the Company has elected to use the contractual life of the option as the expected term for non-employee options. The expected term for performance options is the longer of the explicit or implicit service period. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company’s Board of Directors (the “Board”) may approve the grant of restricted stock units (“RSUs”) pursuant to the Company’s stock incentive plans which represent the right to receive shares of the Company’s common stock based on terms of the agreement. The fair value of RSUs is recognized as share-based compensation expense generally on a straight-line basis over the service period, net of estimated forfeitures. The grant date fair value of an RSU represents the closing price of the Company’s common stock on the date of grant. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Financial instruments recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to valuation techniques as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative issued in connection with the 2020 Convertible Note, further described in Note 5—Debt, was determined by using a Monte Carlo simulation technique (“MCS”) to value the embedded derivative associated with the note. As part of the MCS valuation, a discounted cash flow (“DCF”) model was used to value the debt on a stand-alone basis and determine the discount rate to utilize in both the DCF and MCS models. The significant estimates used in the DCF model include the time to maturity of the convertible debt and calculated discount rate, which includes an estimate of the Company’s specific risk premium. The MCS methodology calculates the theoretical value of an option based on certain parameters, including: (i) the threshold of exercising the option, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate and (vi) the number of paths. These valuation techniques involve management’s estimates and judgment based on unobservable inputs and are classified in Level 3. We expect similar accounting treatment of the debt under the securities purchase agreement and related convertible note described in Note 10—Subsequent Events.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value. As of June 30, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, accounts payable and accrued expenses approximated their fair values due to the short-term nature of the instruments.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering costs consist principally of legal, accounting and underwriters’ fees related to offerings or the Company’s shelf registration statement. Offering costs incurred prior to an offering are initially capitalized and then subsequently reclassified to additional paid-in capital upon completion of the offering. If the equity offering is not completed, any costs deferred will be expensed immediately upon termination of the offering. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with the submission of patent applications are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs included in general and administrative expenses were approximately $158,000 and $132,000 for the three months ended June 30, 2022 and 2021, respectively, and $339,000 and $231,000 for the six months ended June 30, 2022 and 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates net loss per share as a measurement of the Company’s performance while giving effect to all potentially dilutive shares that were outstanding during the reporting period. Because the Company had a net loss for all periods presented, the inclusion of common stock options or other similar instruments would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted net loss per share are the same. For the three and six months ended June 30, 2022 and 2021, 52.2 million and 47.2 million shares, respectively, underlying potentially dilutive warrants and stock options issued and outstanding have been excluded from the computation of diluted weighted average shares outstanding because the effect would be anti-dilutive. The potentially dilutive securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the Innovate 2015 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the 2012 Omnibus Incentive Plan, as amended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,885,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,429,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the 2022 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the Option Grant Agreements granted to RDD Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at a weighted-average exercise price of $55.31 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(expired July 2021)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $2.54</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $3.18</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $0.5894</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,927,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,706,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,220,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,193,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment and the Company’s primary operations are in North America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company adopted this guidance effective January 1, 2022 and the adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements.
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMDU_71eeada4-6a7f-4905-b6e0-57a78adb1fe5">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. These financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary for a fair statement of the balance sheets, operating results, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other future period. Certain information and footnote disclosure normally included in the annual financial statements prepared in accordance with U.S. GAAP have been omitted in accordance with the SEC’s rules and regulations for interim reporting. The Company’s financial position, results of operations and cash flows are presented in U.S. Dollars. These financial statements and related notes should be read in conjunction with the audited financial statements and related notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 23, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below under the section entitled “Recently Issued Accounting Standards—Accounting Pronouncements Adopted,” there have been no material changes to the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared to the significant accounting policies disclosed in Note 1 of the Company’s financial statements for the years ended December 31, 2021 and 2020 included in the Company’s Annual Report on Form 10-K. However, the following accounting policies are the most critical in fully understanding the Company’s financial condition and results of operations.</span></div>
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5NzE_d85ca3ea-856b-457c-bc67-85ce7aea6e28"> Basis of ConsolidationThe accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </us-gaap:ConsolidationPolicyTextBlock>
<nmtr:SaleOfStockShelfRegistrationMaximumEquityOfferingPrice contextRef="if38cffc404754accaf0dd23d052a4bb2_I20201002" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMzM2OQ_4cde67b6-f39e-4e83-94e9-c70a12a97ed7" unitRef="usd"> 200000000 </nmtr:SaleOfStockShelfRegistrationMaximumEquityOfferingPrice>
<nmtr:SaleOfStockATMMaximumEquityOfferingPrice contextRef="i16d10833d39241ada6a6297d1b37e1ef_I20200722" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMzY0NA_1555bca4-ebb9-4474-9b87-2c2d260b3519" unitRef="usd"> 40000000 </nmtr:SaleOfStockATMMaximumEquityOfferingPrice>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="if81448b87fcf45e6a4fb1925e6852af7_D20210330-20210330" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfNDQ0Mg_62e2acb9-d121-4461-a4fc-4f582ac0c450" unitRef="shares"> 30000000 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SharesIssuedPricePerShare contextRef="i301c4447b92b4fc7b2529ac826026bdf_I20210330" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfNDQ5Ng_4b5e2efd-b6b2-4f30-80c8-9066da8cb4ca" unitRef="usdPerShare"> 1.00 </us-gaap:SharesIssuedPricePerShare>
<nmtr:SaleOfStockOptionPeriod contextRef="id3b850aedc9742e0ac828a3c9a3fa186_D20210330-20210330" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMTQ_8e6133e2-b481-48c8-a0b8-8417161ff2cc"> P30D </nmtr:SaleOfStockOptionPeriod>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="id3b850aedc9742e0ac828a3c9a3fa186_D20210330-20210330" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfNDcyMQ_82c3bf60-128c-43e6-a50f-c9ea9e5f89a3" unitRef="shares"> 4500000 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="i921a9f3f4aeb4f53b9d4365718e26462_D20210405-20210405" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfNDkzNg_5e5e2390-02ea-45a8-8cea-20e39190e1cd" unitRef="usd"> 31500000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="i96f38e7cd45047458ef8b2003bee31d6_D20210330-20210330" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfNTMzNg_082dfdda-2405-42e3-bc9d-6c0235bda96d" unitRef="shares"> 450000 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<nmtr:BusinessRisksPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5OTY_7f789a07-2ac5-46d5-80df-3578ca245ba8"> Business RisksThe Company faces risks, including those associated with biopharmaceutical companies whose products are in various stages of development. These risks include, among others, risks related to the Company’s ability to successfully implement its strategic plans; uncertainties associated with the clinical development and regulatory approval of product candidates, including reliance on blinded data; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom, including the Company’s reliance on its lead product candidate; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on the Company’s operations, enrollment in and timing of clinical trials; risks related to leveraging the Company by borrowing money under the debt facility and compliance with its terms; risk of delisting from Nasdaq; reliance on collaborators; reliance on research and development partner; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. </nmtr:BusinessRisksPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5OTg_b3ac787c-b753-4719-bb36-70732283acf7">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three and six months ended June 30, 2022. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
</us-gaap:UseOfEstimates>
<nmtr:AccruedExpensesPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5OTU_c1edd0fc-de1e-438b-829b-eea358b6ee5c">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs periodic expenses such as research and development, licensing fees, salaries and benefits, and professional fees. The Company is required to estimate its expenses resulting from obligations under contracts with clinical research organizations, vendors and consulting agreements that have been incurred by the Company prior to being invoiced. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses as of each balance sheet date based on facts and circumstances known at that time.</span></div>
</nmtr:AccruedExpensesPolicyTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5NzI_53236449-c8bc-45e3-8521-53a34b33453d">
<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.184%"><tr><td style="width:1.0%"/><td style="width:56.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, <br/>2022<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,439,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955,632 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMS0yLTEtMS0zNDg0NQ_a927a229-52a3-4478-9219-aba17343480d" unitRef="usd"> 1421272 </us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMS00LTEtMS0zNDg0NQ_e45f4c1a-e931-4244-bd06-9a2bd55d213e" unitRef="usd"> 1633295 </us-gaap:EmployeeRelatedLiabilitiesCurrent>
<nmtr:AccruedClinicalExpensesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMi0yLTEtMS0zNDg0NQ_764a6c52-656d-482e-a508-78d04721b2e7" unitRef="usd"> 5439111 </nmtr:AccruedClinicalExpensesCurrent>
<nmtr:AccruedClinicalExpensesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMi00LTEtMS0zNDg0NQ_1f868ba5-7135-4696-ab51-5a07e2b5bcc5" unitRef="usd"> 4228048 </nmtr:AccruedClinicalExpensesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMy0yLTEtMS0zNDg0NQ_1c5b9e03-e7d4-4349-8ec1-f910ceb0627a" unitRef="usd"> 95249 </us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfMy00LTEtMS0zNDg0NQ_86d3e610-6b3e-4f54-8ad4-7779cb5740c9" unitRef="usd"> 106479 </us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfNC0yLTEtMS0zNDg0NQ_4392aa10-b7db-4159-bb8b-c38fba984169" unitRef="usd"> 6955632 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjk5YmM5NjZhMGNjYjQyZTNiMmVlZTBkYzc2ZWQzNDEzL3RhYmxlcmFuZ2U6OTliYzk2NmEwY2NiNDJlM2IyZWVlMGRjNzZlZDM0MTNfNC00LTEtMS0zNDg0NQ_f2254361-43fc-455a-a009-6938713fb5d8" unitRef="usd"> 5967822 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DerivativesPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMzA_d822af9f-1f94-46a8-97f3-3cacfbccef13">
Derivative Liability<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative and Hedging, </span>which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the condensed consolidated balance sheet at fair value. There were no outstanding derivative liabilities as of June 30, 2022 or December 31, 2021. Historically, the Company’s derivative financial instruments consisted of embedded options in the Company’s convertible notes, and it expects to have similar accounting treatment of debt under the securities purchase agreement and related convertible note described in Note 10—Subsequent Events.
</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5ODY_ccaab3e1-f32e-469a-a2e4-c82d72eaa6f6">
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred to further the Company’s research and development activities and include salaries and related employee benefits, manufacturing of pharmaceutical active ingredients and drug products, costs associated with clinical trials, nonclinical activities, regulatory activities, research-related overhead expenses and fees paid to expert consultants, external service providers and contract research organizations which conduct certain research and development activities on behalf of the Company. Costs incurred in the research and development of products are charged to research and development expense as incurred.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided by vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. The estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Although the Company does not expect its estimates to be materially different from amounts incurred, the Company’s estimates and assumptions for clinical trial costs could differ significantly from actual costs incurred, which could result in increases or decreases in research and development expenses in future periods when actual results are known.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the goods have been received or when the activity is performed, rather than when payment is made.</span></div>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMzI_fd26692f-f9c8-417d-9d65-39604122390e">
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-process Research and Development </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired, and may in the future acquire, rights to develop and commercialize new drug candidates and/or other in-process research and development assets. The up-front acquisition payments, as well as future milestone payments that are deemed probable to achieve and do not meet the definition of a derivative, are expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and, absent obtaining such approval, have no alternative future use.</span></div>
</us-gaap:InProcessResearchAndDevelopmentPolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5ODg_08b5e3f9-b165-4e91-ba1c-de35a956b577">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense for grants of stock options based on the grant-date fair value of those awards using the Black-Scholes option-pricing model. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service period for awards with time-based vesting. For awards with performance conditions, compensation cost is recognized from the time achievement of the performance criteria is probable over the expected term. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Under the Black-Scholes option-pricing model, fair value is calculated based on assumptions with respect to:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected dividend yield.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected stock-price volatility.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to limited trading history as a public company, the expected volatility is derived from the average historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term. In evaluating comparable companies, the Company considers factors such as industry, stage of life cycle, financial leverage, size and risk profile. </span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Risk-free interest rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Expected term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited history of stock option exercises, the Company estimates the expected term of employee stock options with service conditions based on the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options. Pursuant to Accounting Standards Update (“ASU”) 2018-07, the Company has elected to use the contractual life of the option as the expected term for non-employee options. The expected term for performance options is the longer of the explicit or implicit service period. </span></div>Periodically, the Company’s Board of Directors (the “Board”) may approve the grant of restricted stock units (“RSUs”) pursuant to the Company’s stock incentive plans which represent the right to receive shares of the Company’s common stock based on terms of the agreement. The fair value of RSUs is recognized as share-based compensation expense generally on a straight-line basis over the service period, net of estimated forfeitures. The grant date fair value of an RSU represents the closing price of the Company’s common stock on the date of grant.
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMjU_40ac14c2-2f96-4d0d-bca0-ea8c52500873">
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Financial instruments recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to valuation techniques as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - defined as observable inputs based on unadjusted quoted prices for identical instruments in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - defined as inputs other than Level 1 that are either directly or indirectly observable in the marketplace for identical or similar instruments in markets that are not active; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - defined as unobservable inputs in which little or no market data exists where valuations are derived from techniques in which one or more significant inputs are unobservable.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative issued in connection with the 2020 Convertible Note, further described in Note 5—Debt, was determined by using a Monte Carlo simulation technique (“MCS”) to value the embedded derivative associated with the note. As part of the MCS valuation, a discounted cash flow (“DCF”) model was used to value the debt on a stand-alone basis and determine the discount rate to utilize in both the DCF and MCS models. The significant estimates used in the DCF model include the time to maturity of the convertible debt and calculated discount rate, which includes an estimate of the Company’s specific risk premium. The MCS methodology calculates the theoretical value of an option based on certain parameters, including: (i) the threshold of exercising the option, (ii) the price of the underlying security, (iii) the time to expiration, or expected term, (iv) the expected volatility of the underlying security, (v) the risk-free rate and (vi) the number of paths. These valuation techniques involve management’s estimates and judgment based on unobservable inputs and are classified in Level 3. We expect similar accounting treatment of the debt under the securities purchase agreement and related convertible note described in Note 10—Subsequent Events.</span></div>
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<nmtr:DeferredOfferingCostsPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5NzM_216b2958-2b5f-467c-a89a-c56a2b0e625a"> Deferred Offering CostsDeferred offering costs consist principally of legal, accounting and underwriters’ fees related to offerings or the Company’s shelf registration statement. Offering costs incurred prior to an offering are initially capitalized and then subsequently reclassified to additional paid-in capital upon completion of the offering. If the equity offering is not completed, any costs deferred will be expensed immediately upon termination of the offering. </nmtr:DeferredOfferingCostsPolicyTextBlock>
<nmtr:PatentCostsPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjMwMjc_e0d43175-7895-4308-aee4-f75e18087e49">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Costs associated with the submission of patent applications are expensed as incurred given the uncertainty of the future economic benefits of the patents.
</nmtr:PatentCostsPolicyTextBlock>
<nmtr:PatentAndPatentRelatedCosts contextRef="ie0f9f046f56942218c833782de58823c_D20220401-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjA1MjU_6b1b90c8-dda6-43e1-be4e-8fc46a9df708" unitRef="usd"> 158000 </nmtr:PatentAndPatentRelatedCosts>
<nmtr:PatentAndPatentRelatedCosts contextRef="ic514e4e58330400e8e66a43125acf1bb_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjA1MzI_d818c1f9-c1a8-4dc9-b42c-2fe4cf80fa09" unitRef="usd"> 132000 </nmtr:PatentAndPatentRelatedCosts>
<nmtr:PatentAndPatentRelatedCosts contextRef="icb0bb2e204cd42ad85dcfde88fd781c2_D20220101-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMTA5OTUxMTY1MDgxNw_1c4360c7-9a42-48fc-8a6d-b67d21c6ecde" unitRef="usd"> 339000 </nmtr:PatentAndPatentRelatedCosts>
<nmtr:PatentAndPatentRelatedCosts contextRef="i0b54ca0f248c4c2180a64a364ba47626_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMTA5OTUxMTY1MDgyNg_d6fe395a-9fa2-4070-b0f4-7534f61fcbaa" unitRef="usd"> 231000 </nmtr:PatentAndPatentRelatedCosts>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5Nzc_1143d159-3fd8-476d-ba45-52529ef36510">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>The Company calculates net loss per share as a measurement of the Company’s performance while giving effect to all potentially dilutive shares that were outstanding during the reporting period. Because the Company had a net loss for all periods presented, the inclusion of common stock options or other similar instruments would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted net loss per share are the same.
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjEwOTE_68720ab5-b54d-495a-98a6-38a7e28c70a4" unitRef="shares"> 52200000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjEwOTE_6b9f734e-f346-468f-a108-0b8b3b0c70b4" unitRef="shares"> 52200000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjEwOTg_29cbbee7-3f64-4f2c-bf57-8e73e3823b06" unitRef="shares"> 47200000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjEwOTg_e2aca600-f2d1-4b69-ae79-1ebb74dda2b8" unitRef="shares"> 47200000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5ODM_86bd03ed-a935-41b4-bc42-010197007984">
The potentially dilutive securities consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the Innovate 2015 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,800,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the 2012 Omnibus Incentive Plan, as amended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,885,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,429,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the 2022 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding under the Option Grant Agreements granted to RDD Employees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at a weighted-average exercise price of $55.31 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(expired July 2021)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $2.54</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $3.18</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at an exercise price of $0.5894</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,927,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,706,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,220,051 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,193,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i6e3a31c2c9b4457c9cf9207f415868e6_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMi0yLTEtMS0zNDg0NQ_234d9eb2-88ed-4515-b296-a683aeab634a" unitRef="shares"> 3592248 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ibeefe042a512483fb8bedee119dfe7a2_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMi00LTEtMS0zNDg0NQ_88c9ac8c-ae22-4e91-8881-7f2819663d69" unitRef="shares"> 5800518 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i6a03639bead34176a74878a7f897efd4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMy0yLTEtMS0zNDg0NQ_bd57822e-c2e4-4c48-99a0-6b34ee4ef830" unitRef="shares"> 23885389 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i75f3dd9f369b4cd2b67866451920a537_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMy00LTEtMS0zNDg0NQ_d4df2b42-1804-4469-9cf9-e2bdfb2b4e42" unitRef="shares"> 14429626 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="iaeb54bd17810466d8a5e4677d26ef63e_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNC0yLTEtMS0zODI1OQ_071d3534-0813-4aa0-be1c-576866343ea7" unitRef="shares"> 712545 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i57665d10321a448090db69d73c2676af_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNC00LTEtMS0zODI2NQ_d7668f8b-4705-465a-b40b-76d9c2557ca5" unitRef="shares"> 0 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="idf09e1f4c3c54b11be0b7b6edfeb120b_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNC0yLTEtMS0zNDg0NQ_a7cb3c5c-a0e0-4bb1-86fd-cccac1fb83c0" unitRef="shares"> 985807 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i9624f11c6694442e8b86d7c0670c4810_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNC00LTEtMS0zNDg0NQ_1ed9a890-6dc7-4270-8381-f77d5926f654" unitRef="shares"> 985807 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i7ef4bbc94d9248a3bc54214a8a401388_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNS0wLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjg1ZWViZGQ5OTczNjRiYWU5NGQ1OTg0MWNiZjhlNjc4XzY1_aa11bae7-d3d0-4211-a9df-5cad7df50e8b" unitRef="usdPerShare"> 55.31 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="ic172df7fd57b4ed2a54c5e52a614e238_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNS0yLTEtMS0zNDg0NQ_a0498a8f-760b-4f86-a74c-bf5bf65b545f" unitRef="shares"> 0 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i6c239bad1b6a48f6af846d6a4a0b884f_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNS00LTEtMS0zNDg0NQ_05c101e8-26cb-4cd7-ae23-f4b0753f3263" unitRef="shares"> 154403 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i2fa9516d91b44161bbc7ebe5d6e85591_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNi0wLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjUxNjI1YTYyMjY4YjRjOTQ4ZmNiZTNmMGQ4YTY3ODc2XzQ5_98c04885-fbbe-48e3-936e-bf62b18ec626" unitRef="usdPerShare"> 2.54 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i7a150b589a634d1a894dbf1c81a44e28_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNi0yLTEtMS0zNDg0NQ_4567b14b-9ff1-49cf-ac73-54f1092f2d73" unitRef="shares"> 2233 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i581f34bfe5944e758bbe4d055c506297_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNi00LTEtMS0zNDg0NQ_05b2ba1e-08f6-4081-a351-6084579baf3d" unitRef="shares"> 2233 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="id0191e38b4864eecb9c3bef5f5816578_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNy0wLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjc2MzNiZjNlYTRlMTRmYzZiOWM4N2YwYmUwY2RmMjFmXzQ5_e0b1251c-2243-4573-999d-e9a2d47a670d" unitRef="usdPerShare"> 3.18 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i965ccab740a24bc5bd761270cd4aacb9_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNy0yLTEtMS0zNDg0NQ_3a0adfba-fb21-486d-bd7f-d7dd119bcf97" unitRef="shares"> 113980 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i93f9bd1546344b0fb6ae7d79ec18e277_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfNy00LTEtMS0zNDg0NQ_5eb7424f-3e2f-4630-a659-749ab4afd0e2" unitRef="shares"> 113980 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="ic0fedb90c4e24c208a5d4d200329e6b2_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfOC0wLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjIwYTY4MzM0MDg2ZTQyYjA5MmNmYmM4NWFkODVkZDhlXzQ5_71920675-c38c-4392-890c-0848854d64fc" unitRef="usdPerShare"> 0.5894 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i19cde8898ac44627afe21ef9c7d4df6a_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfOC0yLTEtMS0zNDg0NQ_0881caa7-4adc-4e48-ae6a-6745345e8560" unitRef="shares"> 22927849 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i20d88621004c451e887fca6445ab987f_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfOC00LTEtMS0zNDg0NQ_3c48f626-b518-40d5-8645-433b2c2bade6" unitRef="shares"> 25706449 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMTEtMi0xLTEtMzQ4NDU_e864c964-f995-49ca-a1eb-c52003c562d4" unitRef="shares"> 52220051 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RhYmxlOjQ4ZDM0YjQwZDgyZTQ5YjJhY2EyOTEyNTA1Y2U4MDE3L3RhYmxlcmFuZ2U6NDhkMzRiNDBkODJlNDliMmFjYTI5MTI1MDVjZTgwMTdfMTEtNC0xLTEtMzQ4NDU_4771763f-dc6b-48e5-9276-04e6419807d5" unitRef="shares"> 47193016 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5OTE_5d147516-5c32-44ca-9ac6-b1b7865e7e00">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:NumberOfOperatingSegments contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjE3NDA_9c54a543-96ae-40d9-a972-cdadae89e79b" unitRef="segment"> 1 </us-gaap:NumberOfOperatingSegments>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zMS9mcmFnOjk2MDU3ODk4ZGFmNDRiNDg4MDkzNjRhNGY1MWE3NTRlL3RleHRyZWdpb246OTYwNTc4OThkYWY0NGI0ODgwOTM2NGE0ZjUxYTc1NGVfMjI5NzA_22efcebf-12b5-4f82-b014-162a8d17f0b2">
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span>, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company adopted this guidance effective January 1, 2022 and the adoption of ASU 2020-06 did not have a material impact on the Company’s condensed consolidated financial statements.
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zNy9mcmFnOmUwYjE0YTQyMzNkYzRiMDdiNzQ3ZjU1ZjY1OWE5YjFiL3RleHRyZWdpb246ZTBiMTRhNDIzM2RjNGIwN2I3NDdmNTVmNjU5YTliMWJfMTczMw_5631d208-bab2-4ec8-a1f0-64483605ed02">
LIQUIDITY AND GOING CONCERN<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.5 million. The Company expects to incur substantial losses in the future as it progresses its current product pipeline, seeks regulatory approval for product candidates and prepares for commercialization. </span></div>Based on the Company’s limited operating history, recurring negative cash flows from operations, current plans and available resources, the Company will need substantial additional funding to support future operating activities. The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by the Company raise substantial doubt about the Company’s ability to continue as a going concern for at least one year following the date these financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company may seek to raise additional funding through dilutive and non-dilutive financings. There can be no assurance that the Company will be able to obtain additional capital on terms acceptable to the Company, on a timely basis or at all. The failure to obtain sufficient additional funding could adversely affect the Company’s ability to achieve its business objectives and product development timelines and could have a material adverse effect on the Company’s results of operations.
</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl8zNy9mcmFnOmUwYjE0YTQyMzNkYzRiMDdiNzQ3ZjU1ZjY1OWE5YjFiL3RleHRyZWdpb246ZTBiMTRhNDIzM2RjNGIwN2I3NDdmNTVmNjU5YTliMWJfMzYw_3bbdc4f1-4975-4bd5-9821-9b4419f48336" unitRef="usd"> 29500000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<nmtr:AssetAcquisitionDisclosureTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfMTgxMQ_6d579087-aeea-4994-80fd-0aaef9d996c1">
ACQUISITION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lobesity Acquisition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, the Company closed an asset purchase agreement (the “Lobesity Asset Purchase Agreement”) with Lobesity LLC (“Lobesity”) pursuant to which the Company acquired global development rights to a proprietary and highly specific humanized monoclonal antibody that targets glucose-dependent insulinotropic polypeptide, as well as related intellectual property (the “Lobesity Acquisition”). The consideration for the Lobesity Acquisition at closing consisted of $2.3 million in cash and 2,417,211 shares of unregistered common stock plus the right to contingent payments including certain potential worldwide regulatory and clinical milestone payments totaling $45.5 million for a single indication (with the total amount payable, if multiple indicates are developed, not to exceed $58.0 million), global sales-related milestone payments totaling up to $50.0 million, and, subject to certain adjustments, a mid-single digit royalty on worldwide net sales.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To satisfy the Company’s post-closing rights to indemnification under the Lobesity Asset Purchase Agreement, 604,303 of the shares issued to Lobesity are subject to holdback restrictions for 18 months following closing of the transaction. The Company’s right to indemnification will be satisfied through the recovery of these shares or paid in cash by Lobesity.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lobesity Acquisition was accounted for as an asset acquisition under ASU 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span>. The net tangible and intangible assets acquired, and liabilities assumed in connection with the transaction were recorded at their estimated fair values on the date of acquisition. The excess of purchase price over fair value of identified assets acquired and liabilities assumed was expensed as in-process research and development.
</nmtr:AssetAcquisitionDisclosureTextBlock>
<nmtr:PaymentsForAssetAcquisition contextRef="i8f80ec38c797462c94460631f26a5ac8_D20210719-20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfNTIw_4440f088-347f-46ff-93a7-640fc84e38ba" unitRef="usd"> 2300000 </nmtr:PaymentsForAssetAcquisition>
<nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares contextRef="i8f80ec38c797462c94460631f26a5ac8_D20210719-20210719" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfNTM1_852209e4-c8b9-4086-964f-9bf401bad77c" unitRef="shares"> 2417211 </nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares>
<nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments contextRef="ia57c0801b472477e970c138f50696801_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfNzAy_21ceb836-816b-42bd-8645-e2b9b2cf8cd9" unitRef="usd"> 45500000 </nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments>
<nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments contextRef="ic98cfc730ffd404c867befe1cc8978e7_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfODEy_eb36a53f-69bd-4f94-be30-95f4be9ba245" unitRef="usd"> 58000000 </nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments>
<nmtr:AssetAcquisitionSalesRelatedMilestonePayments contextRef="ic98cfc730ffd404c867befe1cc8978e7_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfODcy_fc8ae199-0129-43cb-8e8d-c6745ac0e4f8" unitRef="usd"> 50000000 </nmtr:AssetAcquisitionSalesRelatedMilestonePayments>
<nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableSubjectToRestrictionsNumberOfShares contextRef="i8f80ec38c797462c94460631f26a5ac8_D20210719-20210719" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfMTA3NA_8bd3ebb3-e849-4040-8f60-41cd63f80d4f" unitRef="shares"> 604303 </nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableSubjectToRestrictionsNumberOfShares>
<nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableRestrictionPeriod contextRef="i8f80ec38c797462c94460631f26a5ac8_D20210719-20210719" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80MC9mcmFnOjI5Y2I0N2FkMWM0ZDQwMWE5MTRlZGFiYWRiZDY3NDdmL3RleHRyZWdpb246MjljYjQ3YWQxYzRkNDAxYTkxNGVkYWJhZGJkNjc0N2ZfMTE1MQ_6ed89d1a-fe03-4051-b349-7177037e8302"> P18M </nmtr:AssetAcquisitionEquityInterestIssuedOrIssuableRestrictionPeriod>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfNzAx_a90f5cc5-2a67-4ca1-89d0-3b800b5eeaed"> RELATED PARTY TRANSACTIONSMichael Rice, a member of our Board since March 2021, is a Founding Partner of LifeSci Advisors, LLC and LifeSci Communications, LLC. Prior to his becoming a director, on April 1, 2020 the Company entered into a master services agreement with both LifeSci Advisors, LLC and LifeSci Communications, LLC, to provide investor relations and public relations services, respectively. The Company incurred expenses with LifeSci Advisors, LLC of approximately $64,000 and $127,000 during the three and six months ended June 30, 2022, respectively, and $66,000 and $176,000 during the three and six months ended June 30, 2021, respectively. The Company incurred expenses with LifeSci Communications, LLC of approximately $70,000 and $144,000 during the three and six months ended June 30, 2022, respectively, and $63,000 and $190,000 during the three and six months ended June 30, 2021, respectively. </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i70d54165797841aab839a7bb6f8cb2aa_D20220401-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfNDkz_35e038f2-1288-4ba7-87c1-b95156268d2d" unitRef="usd"> 64000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i43a2af6a9e3e4a75a459691d4e2ee7f3_D20220101-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfNTAw_53b8919d-4563-40fa-bb67-8a19fe773d9a" unitRef="usd"> 127000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i3c68946b20ec41c490480e246357aba4_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfMTA5OTUxMTYyODYzOA_2f99475e-db0d-4f8c-a485-bdcc8c9965c0" unitRef="usd"> 66000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i09064597d0eb438386926ff90cca0a2b_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfMTA5OTUxMTYyODY0Nw_806a1f91-c9eb-49f0-ba53-346b599fdcc2" unitRef="usd"> 176000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i7f64e8aabc014f929102522aa260e9b1_D20220401-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfNjM3_1ba7c777-b669-4d43-8dfb-8e13e5e0b393" unitRef="usd"> 70000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i357ce8577cab458db9ad05c0e2281b5b_D20220101-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfNjQ0_124ea03d-12d4-4992-b8af-f83f7ef15603" unitRef="usd"> 144000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="i1abf5da9853343ff85b2f34205be0f90_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfMTA5OTUxMTYyODY3Ng_5272f145-2528-4723-b895-d1ab15b23bae" unitRef="usd"> 63000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="ifcf1d2d3875c49e78693ff75bd2c31dd_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80My9mcmFnOmRiZWYwM2Y3MDNlMjRkMjA5MzcyYzJmZGExOTZlZjNkL3RleHRyZWdpb246ZGJlZjAzZjcwM2UyNGQyMDkzNzJjMmZkYTE5NmVmM2RfMTA5OTUxMTYyODY4NQ_58e8ccdf-3e8a-4041-8254-2ecd1a91fd90" unitRef="usd"> 190000 </us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:DebtDisclosureTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTQ5MQ_7850c0ba-f067-4028-a956-43154e8d1ee9">
DEBT <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Convertible Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2020, the Company entered into a securities purchase agreement and unsecured convertible promissory note in the principal amount of $2,750,000 (the “2020 Convertible Note”). The convertible noteholder could elect to convert all or a portion of the 2020 Convertible Note, at any time from time to time into the Company’s common stock at a conversion price of $3.25 per share, subject to adjustment for stock splits, dividends, combinations and similar events. The purchase price of the 2020 Convertible Note was $2,500,000 and carried an original issuance discount of $250,000, which was included in the principal amount. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various conversion and redemption features contained in the 2020 Convertible Note were embedded derivative instruments, which were recorded as a debt discount and derivative liability at the issuance date at their estimated fair value of $0.4 million. Amortization of the debt discount and accretion of the OID for the 2020 Convertible Note recorded as interest expense was approximately $44,000 for the six months ended June 30, 2021. There was no interest expense incurred during the three months ended June 30, 2021 or the three and six months ended June 30, 2022.</span></div>The 2020 Convertible Note bore interest at the rate of 10% per annum, compounding on a daily basis. During the six months ended June 30, 2021, the Company paid the remaining balance of principal and interest on the 2020 Convertible Note of approximately $59,000 in cash.
</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DebtInstrumentFaceAmount contextRef="ib0eced5ce7c74957aa804c51c9415f47_I20200110" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTg1_00d25be0-d832-4321-882c-b5948fd18c6c" unitRef="usd"> 2750000 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="ib0eced5ce7c74957aa804c51c9415f47_I20200110" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMzkz_6362bf45-cda2-4796-b868-bdca0aabbc67" unitRef="usdPerShare"> 3.25 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="i513c677c005d4719b6b2611cfb8d821a_D20200110-20200110" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfNTM4_4f82b7b5-5802-4c5f-af7e-9112bdc800ad" unitRef="usd"> 2500000 </us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="ib0eced5ce7c74957aa804c51c9415f47_I20200110" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfNTg2_5e4f6b52-c94f-42e7-b7ec-6bc42a6da0c5" unitRef="usd"> 250000 </us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="ib0eced5ce7c74957aa804c51c9415f47_I20200110" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfODk3_5a129a77-417e-4f7a-9047-41e37c8ea83e" unitRef="usd"> 400000 </us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="ifbb87cf463714c00b4d05b1242040abf_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTAzNg_b1072ae6-1b12-4572-997f-64c8c4a0e74c" unitRef="usd"> 44000 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="i39decf0bdd70488287e87612a951f343_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTA5Mg_3babbceb-1ac5-49c0-8b51-ef5e7777175f" unitRef="usd"> 0 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="i220e71dc53a545dfa7ae595b11c88b4a_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTA5Mg_ab3f38f1-f308-452f-a4e7-340c56c222ef" unitRef="usd"> 0 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="id7889241ee654c68a44582761f4be1cf_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTA5Mg_e8a8d084-8e53-42cb-828a-647dbf3171ff" unitRef="usd"> 0 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="ib0eced5ce7c74957aa804c51c9415f47_I20200110" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTIxOA_932a29fe-9b3b-40cf-a08c-3e44c15bda68" unitRef="number"> 0.10 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:RepaymentsOfDebt contextRef="ifbb87cf463714c00b4d05b1242040abf_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80Ni9mcmFnOjI1NzRiMDA0MzNhMTQwNzE4YjhiNTQ2YThmNWY5NGE0L3RleHRyZWdpb246MjU3NGIwMDQzM2ExNDA3MThiOGI1NDZhOGY1Zjk0YTRfMTQxNA_68193ca5-992f-4677-8639-c41b6146ee76" unitRef="usd"> 59000 </us-gaap:RepaymentsOfDebt>
<nmtr:LicenseAgreementsTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjI0OQ_9ab66be5-e617-4d40-865b-373ababb3e97">
LICENSE AGREEMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alba License</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2016, the Company entered into a license agreement (the “Alba License”) with Alba Therapeutics Corporation (“Alba”) to obtain the rights to certain intellectual property relating to larazotide acetate and related compounds. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the Alba License, the Company paid Alba a non-refundable license fee of $0.5 million. In addition, the Company is required to make milestone payments to Alba upon the achievement of certain clinical and regulatory milestones totaling up to $1.5 million and payments upon regulatory approval and commercial sales of a licensed product totaling up to $150 million, which is based on sales ranging from $100 million to $1.5 billion.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the Company paying Alba $2.5 million for the first commercial sale of a licensed product, the Alba License becomes perpetual and irrevocable. Upon the achievement of net sales in a year exceeding $1.5 billion, the Alba License also becomes free of milestone fees. The Alba License provides Alba with certain termination rights, including failure of the Company to use Commercially Reasonable Efforts (as defined in the Alba License) to develop the licensed products. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seachaid Agreement</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into an exclusive license agreement with Seachaid Pharmaceuticals, Inc. (the “Seachaid Agreement”) to further develop and commercialize the licensed product, the compound known as APAZA. The Company was required to make an initial, non-refundable payment under the Seachaid Agreement in the amount of $0.2 million. The agreement also calls for milestone payments totaling up to $6.0 million to be paid when certain clinical and regulatory milestones are met. There are also commercialization milestone payments ranging from $1.0 million to $2.5 million depending on net sales of the products in a single calendar year, followed by royalty payments in the single digits based on net product sales.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repligen Agreement</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2014, the Company entered into an asset purchase agreement (the “Repligen Asset Purchase Agreement”) with Repligen Corporation (“Repligen”) to acquire Repligen’s RG-1068 program for the development of Secretin for the Pancreatic Imaging Market and Magnetic Resonance Cholangiopancreatography. As consideration for the Repligen Asset Purchase Agreement, the Company agreed to make a non-refundable cash payment on the date of the agreement and future royalty payments consisting of a percentage between five and fifteen of annual net sales, with the royalty payment percentage increasing as annual net sales increase. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amunix Licenses</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Naia Rare Diseases, Inc. (the “Naia Acquisition”), the Company entered into two amended and restated license agreements with Amunix Pharmaceuticals, Inc. (“Amunix”), pursuant to which the Company received an exclusive, worldwide, royalty-bearing license, with rights of sublicense, to lead molecules GLP-1 and GLP-2 along with a related XTEN sequence and other intellectual property referenced therein (the “Amunix Licenses”). Also in connection with the Naia Acquisition, the Company entered into an amended and restated license agreement with Cedars-Sinai Medical Center (“Cedars”), pursuant to which the Company licensed the rights to GLP-1 Agonist for the treatment of SBS (the “Cedars License”). </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration under the Amunix License for GLP-1, the Company agreed to pay Amunix certain royalty payments and (i) $70.4 million in milestone payments upon achievement of future development and sales milestones in the U.S. and major EU countries, (ii) $20.5 million in milestone payments upon achievement of future development and sales milestones in China and certain related territories, and (iii) $20.5 million in milestone payments upon achievement of future development and sales milestones in South Korea and certain other East Asian countries. As consideration under the Amunix License for GLP-2, the Company agreed to pay Amunix certain royalty payments and $60.1 million in milestone payments upon achievement of future development and sales milestones in the U.S. and major EU countries.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration under the Cedars License, the Company agreed to pay Cedars certain royalty payments and approximately $9.4 million in milestone payments upon achievement of future development and sales milestones.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MHS License</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the assets acquired in the Lobesity Acquisition was an amended and restated technology license agreement with MHS Care-Innovation LLC (“MHS”), pursuant to which the Company received an exclusive, worldwide license, with rights to sublicense, to certain patent and other intellectual property rights concerning a proprietary and highly specific humanized monoclonal antibody that targets glucose-dependent insulinotropic polypeptide (the “MHS License”). The MHS License does not require the payment of any future milestone payments or royalties to MHS, since it was originally entered into with Lobesity in exchange for the issuance of certain equity securities and a grant of certain related rights to Lobesity, all of which occurred prior to the closing of the Lobesity Acquisition. As consideration for the assets purchased in the Lobesity Acquisition (including but not limited to the MHS License), the Company is obligated to pay Lobesity (i) potential worldwide regulatory and clinical milestone payments totaling $45.5 million for a single indication (with the total amount payable, if multiple indications are developed, not to exceed $58.0 million), (ii) up to $50.0 million in global sales-related milestone payments, and (iii) subject to certain adjustments, a mid-single digit royalty on worldwide net sales. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EBRIS Collaboration</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company announced a collaboration with the European Biomedical Research Institute of Salerno, Italy (“EBRIS”) to study larazotide for the treatment of MIS-C. In connection with this collaboration, the Company paid a milestone fee of $0.5 million upon IND approval for MIS-C. Following receipt of a Study May Proceed letter from the FDA under the Investigator IND, EBRIS initiated a Phase 2a study in MIS-C during the fourth quarter of 2021. The Phase 2a study is a randomized, double-blind, placebo-controlled study. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, the Company entered into an exclusive license agreement (the “EBRIS License Agreement”) with EBRIS pursuant to which the company granted to EBRIS an exclusive license to study the Company’s product incorporating larazotide as its sole active pharmaceutical ingredient (the “Product”) for the treatment of MIS-C and, potentially, multisystem inflammatory syndrome in adults (“MIS-A”). In turn, the Company will have an option to license from EBRIS any new intellectual property resulting from such development (the “Option”).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the EBRIS License Agreement, the Company issued to EBRIS shares of common stock valued at $500,000 (consisting of 871,962 shares of unregistered common stock priced at the Company’s 20-day volume weighted-price as of the date of closing), plus the Company will pay EBRIS $500,000 in cash in connection with final database lock of the ongoing Phase II clinical trial for the treatment of MIS-C. Upon the readout of the top-line data and an FDA agreed upon path forward to further develop the compound in MIS-C, the Company may exercise the Option for an upfront fee of $1 million. In addition, the EBRIS License Agreement contemplates certain contingent payments, including development milestone payments, sales-related milestone payments, and subject to certain adjustments, a low-single digit royalty on net sales of Products in the United States sold pursuant to prescriptions for use in treating MIS-C and, if applicable, MIS-A. Of note, each such payment is payable, at the option of the Company, in cash or a combination of cash and unregistered shares of the Company’s common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the right to exercise the Option until three months following the later of (i) the end of the Development Term (as defined in the EBRIS License Agreement) and (ii) the delivery by EBRIS to the Company of the material Know-How (as defined in the EBRIS License Agreement) and final study reports (the “Option Expiration Date”). Unless earlier terminated, the term of the EBRIS License Agreement will continue (i) if the Company does not exercise the Option, until the Option Expiration Date or (ii) if the Company exercises the Option, on a product-by-product and country-by-country basis, until the expiration of the Company’s royalty obligations for each product in a particular country. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Option Expiration Date, the EBRIS License Agreement may be terminated by the Company for convenience upon two months’ prior written notice to EBRIS. The EBRIS License Agreement may be terminated by either party upon (i) a material breach by the other party (subject to prior written notice and a cure period), (ii) certain insolvency events, including bankruptcy proceedings, or (iii) written notice that, as reasonably determined in good faith by the terminating party, termination is necessary to protect the health or safety of trial participants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the EBRIS License Agreement will automatically terminate if the Alba License terminates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EBRIS License Agreement includes standard and customary provisions regarding, among other things, compliance with laws and regulations, confidentiality, intellectual property, representations and warranties, liability, indemnification, and insurance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Fees</span></div>The Company incurred milestone fees of $0.5 million, which were paid in equity to EBRIS, during the three and six months ended June 30, 2022. There were no milestone fees incurred during the three and six months ended June 30, 2021.
</nmtr:LicenseAgreementsTextBlock>
<nmtr:LicenseFees contextRef="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMzcy_455a05e1-c9ca-4e0e-bd5e-503edb98e430" unitRef="usd"> 500000 </nmtr:LicenseFees>
<nmtr:MilestonePayment contextRef="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNTMw_99358326-69c9-4832-a6f6-69ec65147712" unitRef="usd"> 1500000 </nmtr:MilestonePayment>
<nmtr:MaximumPotentialFutureCommercialMilestonePayment contextRef="if70accbc173f4cdfadb0ae1d83aea369_D20160101-20161231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjI5_a17a6a33-2601-4e6b-91f9-90893339a699" unitRef="usd"> 150000000 </nmtr:MaximumPotentialFutureCommercialMilestonePayment>
<nmtr:SalesRangeMinimum contextRef="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjcw_54047fdf-6e1b-40f8-a231-246760ece570" unitRef="usd"> 100000000 </nmtr:SalesRangeMinimum>
<nmtr:SalesRangeMaximum contextRef="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231" decimals="-8" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjc2_b32dae76-764d-47fa-b840-d31e1787af79" unitRef="usd"> 1500000000 </nmtr:SalesRangeMaximum>
<nmtr:AggregateMilestoneFeesPerpetualLicenseTrigger contextRef="if70accbc173f4cdfadb0ae1d83aea369_D20160101-20161231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNzEw_41768a2e-1e76-4ade-9271-dbda4d8ad437" unitRef="usd"> 2500000 </nmtr:AggregateMilestoneFeesPerpetualLicenseTrigger>
<nmtr:MilestoneFeeFreeSalesTargetValue contextRef="i41ff1bf0eef84129ba72a76d868fe40a_D20160101-20161231" decimals="-8" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfODcy_27faaab5-b356-49ca-96e5-d0f1bbfa769c" unitRef="usd"> 1500000000 </nmtr:MilestoneFeeFreeSalesTargetValue>
<nmtr:LicenseFees contextRef="i6115352c34e14b0898b4bbfb7f3ad2d1_D20130101-20131231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTQ5MA_b010c6d3-507f-4d7f-95ff-d1f4da6a0daa" unitRef="usd"> 200000 </nmtr:LicenseFees>
<nmtr:MilestonePayment contextRef="i6115352c34e14b0898b4bbfb7f3ad2d1_D20130101-20131231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTU1Nw_c68c17e4-9b66-4a8b-8772-3881d03c7fa7" unitRef="usd"> 6000000 </nmtr:MilestonePayment>
<nmtr:SalesRangeMinimum contextRef="i6115352c34e14b0898b4bbfb7f3ad2d1_D20130101-20131231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTY5Mw_0dc6ade2-84d9-400e-9de5-b7f215b95062" unitRef="usd"> 1000000 </nmtr:SalesRangeMinimum>
<nmtr:SalesRangeMaximum contextRef="i6115352c34e14b0898b4bbfb7f3ad2d1_D20130101-20131231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTY5OQ_d78a99ca-cf51-4622-aa1a-ac4d7c69029d" unitRef="usd"> 2500000 </nmtr:SalesRangeMaximum>
<nmtr:RoyaltyPaymentPercentage contextRef="i6cd6d83970004f30b38f9c95197bc218_D20140101-20141231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjM3Nw_67578f6e-0ed5-42b2-a12d-f671fe04ec82" unitRef="number"> 0.05 </nmtr:RoyaltyPaymentPercentage>
<nmtr:RoyaltyPaymentPercentage contextRef="i153dbae8537248c49190e3ec7bb0715d_D20140101-20141231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjM4NA_e7184223-3c4c-492a-900f-a6d204fd221c" unitRef="number"> 0.15 </nmtr:RoyaltyPaymentPercentage>
<nmtr:NumberOfAmendedAndRestatedLicenseAgreements contextRef="i038b6fb2db5f4a3db03d11e6dd970707_I20200506" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjU3MA_191281df-340d-4f52-bf6d-4aa7a5c1de0c" unitRef="licenseagreement"> 2 </nmtr:NumberOfAmendedAndRestatedLicenseAgreements>
<nmtr:MilestonePayment contextRef="i5ca1e354b1ab4544b5978732be05e8c4_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMzMxNw_4cf4fc9f-af15-471f-b095-4bb5b9dd9543" unitRef="usd"> 70400000 </nmtr:MilestonePayment>
<nmtr:MilestonePayment contextRef="ibd28aaa15bb848869f9cd4e67c14ee03_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMzQ0Mw_7c53c328-b8a9-450c-9cca-4bdd37eebb6d" unitRef="usd"> 20500000 </nmtr:MilestonePayment>
<nmtr:MilestonePayment contextRef="i5b37ffe504664c04b9d65041e4e4ff35_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMzU4MA_9281ac8a-1314-4817-89fe-ec9762a3a9f0" unitRef="usd"> 20500000 </nmtr:MilestonePayment>
<nmtr:MilestonePayment contextRef="id06ba912253f4083bc6bef0d663e5bd0_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMzgzNQ_6908fdcb-26f1-43a9-a294-86ce7fe0be42" unitRef="usd"> 60100000 </nmtr:MilestonePayment>
<nmtr:MilestonePayment contextRef="i72abcf3a41534573be4fd652117a6875_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNDA3Ng_2cf4a980-77af-45f9-8142-e5ab0377aa00" unitRef="usd"> 9400000 </nmtr:MilestonePayment>
<nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments contextRef="ib996466d42d141c4af134baa567200ca_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNTIwMg_9720fa35-f5c3-4202-9b5d-8f7819463361" unitRef="usd"> 45500000 </nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments>
<nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments contextRef="i84d767bafe5345abb698cd0203027f61_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNTMxNA_c6400809-dabe-4929-8226-676102352203" unitRef="usd"> 58000000 </nmtr:AssetAcquisitionRegulatoryAndClinicalMilestonePayments>
<nmtr:AssetAcquisitionSalesRelatedMilestonePayments contextRef="i84d767bafe5345abb698cd0203027f61_I20210719" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNTMzMA_d545f523-c567-41dc-90bf-1005c1520ad6" unitRef="usd"> 50000000 </nmtr:AssetAcquisitionSalesRelatedMilestonePayments>
<nmtr:MilestonePayment contextRef="i9f9ff1ca2e9b45f4b6297ce52b9367df_D20210816-20210816" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNTc0OQ_a56573dc-738f-4f33-8fbc-058f7e2a98ff" unitRef="usd"> 500000 </nmtr:MilestonePayment>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="i19542c94858d4f24acbd5600b34107a2_D20220411-20220411" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjc0ODc3OTA3OTI5Mg_a77de4a8-4034-4f2f-ba14-bd7097596517" unitRef="usd"> 500000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="ic9b00aabc8144d3bba98652d8844fce1_D20220411-20220411" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjc0ODc3OTA3OTMxMQ_c14a5108-94d1-4636-9e34-17442275d99c" unitRef="shares"> 871962 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<nmtr:MilestonePayment contextRef="i3ad873508e374cbabbfeb8d6e2f6f107_D20220411-20220411" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjc0ODc3OTA3OTMzMA_7c99dbc1-af34-4474-94ce-6ed17914380f" unitRef="usd"> 500000 </nmtr:MilestonePayment>
<nmtr:LicenseFees contextRef="i3ad873508e374cbabbfeb8d6e2f6f107_D20220411-20220411" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMjc0ODc3OTA3OTM1MQ_dd3714ad-e556-40fe-b3cb-e9b2a8ba647c" unitRef="usd"> 1000000 </nmtr:LicenseFees>
<nmtr:AccruedMilestoneFees contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTA5OTUxMTYzNzYwNQ_1e1fa2e1-d884-4b15-bd3a-bd151b00cf5c" unitRef="usd"> 500000 </nmtr:AccruedMilestoneFees>
<nmtr:AccruedMilestoneFees contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfMTA5OTUxMTYzNzYwNQ_23ee4162-c003-4821-90fd-4e39dc2b6e3d" unitRef="usd"> 500000 </nmtr:AccruedMilestoneFees>
<nmtr:AccruedMilestoneFees contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjE2Ng_a64beae0-f555-49e3-93b4-42233fdcd549" unitRef="usd"> 0 </nmtr:AccruedMilestoneFees>
<nmtr:AccruedMilestoneFees contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl80OS9mcmFnOjA2ZmVmZTdjYmVjODQ4ZTg5ZTU1M2Q4YWY0ZmRjZjM4L3RleHRyZWdpb246MDZmZWZlN2NiZWM4NDhlODllNTUzZDhhZjRmZGNmMzhfNjE2Ng_cad26a78-5f83-497d-b12a-d7c38669af2b" unitRef="usd"> 0 </nmtr:AccruedMilestoneFees>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTk0Ng_2867a4ce-6ed9-4c60-99ab-844c13d2c4cc">
STOCKHOLDERS’ EQUITY<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s amended and restated certificate of incorporation, as amended in June 2021, authorizes 560 million shares of capital stock, par value $0.0001 per share, of which 550 million shares are designated as common stock and 10 million shares are designated as preferred stock.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s amended and restated certificate of incorporation, as amended, authorizes the Board to issue preferred stock in one or more classes or one or more series within any class from time to time. Voting powers, designations, preferences, qualifications, limitations, restrictions or other rights will be determined by the Board at that time. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no shares of preferred stock issued and outstanding as of June 30, 2022 or December 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Company’s common stock (i) have equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board; (ii) are entitled to share in all the Company’s assets available for distribution to holders of common stock upon liquidation, dissolution or winding up of the Company’s affairs; (iii) do not have preemptive, subscription or conversion rights (and there are no redemption or sinking fund provisions or rights); and (iv) are entitled to one non-cumulative vote per share on all matters on which stockholders may vote. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 259,107,380 and 258,235,418 shares of common stock outstanding as of June 30, 2022 and December 31, 2021, respectively. The Company had reserved shares of common stock for future issuance as follows: </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 <br/>(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,894,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,044,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,044,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For possible future issuance under the 2022 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total common shares reserved for future issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507,506 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,417,616 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div>The Company entered into the Sales Agreement dated July 22, 2020, and as amended on October 2, 2020, with Truist relating to the 2020 ATM. During the three and six months ended June 30, 2022 and 2021, there were no shares sold under the 2020 ATM. Pursuant to the sales agreement, the Company will pay Truist a commission rate of 3.0% of the gross proceeds from the sale of any shares of common stock under the 2020 ATM.
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<nmtr:CapitalStockSharesAuthorized contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTM3_5a6b42fb-dc58-42e6-94a4-4860bb74adcb" unitRef="shares"> 560000000 </nmtr:CapitalStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTc1_039f7a1c-f694-4ab5-80ad-d716ac2b41fb" unitRef="usdPerShare"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTk4_87d06de9-2646-445e-9506-800304de819f" unitRef="shares"> 550000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="i795078817fa04a78822210551ff1c072_I20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMjQz_4893472f-b54c-4302-a153-202b6c885cf3" unitRef="shares"> 10000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfNjY5_63dcec03-459f-4427-b378-a9d21d604a84" unitRef="shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfNjY5_badcf5e9-7098-4f12-a167-00053d1b0f26" unitRef="shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTM3NA_8a3e0e59-3f27-457d-b71d-4d0b08f2b638" unitRef="shares"> 259107380 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTA5OTUxMTYyOTc2OQ_5d766ed2-7017-472e-8442-a6d4e2a21c8d" unitRef="shares"> 258235418 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:ScheduleOfStockByClassTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTk0Mg_bb10fb5a-5d5e-43ab-b655-ad72dcfc43a6">
The Company had reserved shares of common stock for future issuance as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 <br/>(Unaudited)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175,989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,894,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,044,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,044,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For possible future issuance under the 2022 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,287,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total common shares reserved for future issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507,506 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,417,616 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table>
</us-gaap:ScheduleOfStockByClassTextBlock>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i6fdb727dcd0c451bb9e6150fb5881d51_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfMi0yLTEtMS0zNDg0NQ_0717e998-de25-42cc-bace-d6e58ed4f126" unitRef="shares"> 29175989 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i50d2d2d25d354e2d9fac418a6e6f8752_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfMi0zLTEtMS0zNDg0NQ_7b4b5295-2ecc-4e7c-8275-7419a5923369" unitRef="shares"> 20894767 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i2969c8cf7c564cbe8ad83fb88268cb40_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfMy0yLTEtMS0zNDg0NQ_4ca4274c-76aa-4bf0-963e-809159ae5486" unitRef="shares"> 23044062 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i9f94dd28c5ee44c9a26c83cd74475922_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfMy0zLTEtMS0zNDg0NQ_328398e6-e15e-4c81-8cc9-d91c3a6cfa3c" unitRef="shares"> 23044062 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfNi0yLTEtMS0zNDg0NQ_d23ef94d-a18a-4100-8a23-1123e01e1577" unitRef="shares"> 11287455 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i71ca31d8ff2b41d9acab4d38e431d956_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfNi0zLTEtMS0zNDg0NQ_4ac74de9-11c9-4249-95a0-0309492aaa8d" unitRef="shares"> 5478787 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfNy0yLTEtMS0zNDg0NQ_fed90b87-e56d-4a97-974f-12d323b79fae" unitRef="shares"> 63507506 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RhYmxlOmE0ZWQ2ZGRiNTAyYzRiMzRhZTU5MzFhYzk3NTkxOTc1L3RhYmxlcmFuZ2U6YTRlZDZkZGI1MDJjNGIzNGFlNTkzMWFjOTc1OTE5NzVfNy0zLTEtMS0zNDg0NQ_810ed945-e944-4bc3-8aba-d26a8755b914" unitRef="shares"> 49417616 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="ia0949f0f5ce14efc8723d5575f9b0212_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTczNA_779bd226-7ea0-444b-b853-3b30139dd1cb" unitRef="shares"> 0 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="ic95046b1850b4d0cbd64dc392881e2e4_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTczNA_8dd81e50-8cdc-49cb-a0fb-b56bf4e6907f" unitRef="shares"> 0 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="i5c797acfda3d487abfe84bc25836d4fb_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTczNA_8e07b2f5-7e9b-45f1-acf9-039fc067900a" unitRef="shares"> 0 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="i4b6ca1a4a4b14b5db7e03ac606396726_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTczNA_ac3a5571-feec-4d5b-8e69-a9afae9403db" unitRef="shares"> 0 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<nmtr:SaleOfStockAgentCommissionFees contextRef="i2ee548f79fb84de391b927032650460d_D20220101-20220630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81Mi9mcmFnOjNlMjE1N2E0OGM5NjRiMTk4Njk5YmE1NDRjNTk4M2I1L3RleHRyZWdpb246M2UyMTU3YTQ4Yzk2NGIxOTg2OTliYTU0NGM1OTgzYjVfMTg1MQ_a630e33a-40f5-492d-8421-3c12340734af" unitRef="number"> 0.030 </nmtr:SaleOfStockAgentCommissionFees>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQ3MQ_d3123e67-1f24-453e-a431-93b4543ddd8d">
SHARE-BASED COMPENSATION <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three stock option plans in existence: the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan (the “2022 Plan”), the 2012 Omnibus Incentive Plan, as amended (the “Omnibus Plan”) and the Innovate 2015 Stock Incentive Plan (the “Private Innovate Plan”). In addition, the Company assumed 1,014,173 options in accordance with the terms of the merger agreement with RDD Pharma, Ltd. (the “RDD Merger Agreement”). The Company’s stock options typically vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzk0_3b893c6b-2915-41df-83f7-f458c0885f58">three</span> or four years and typically have a maximum term of ten years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 Stock Incentive Plan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there were 3,592,248 stock options outstanding under the Private Innovate Plan. Since 2018, the Company has not issued, and does not intend to issue, any additional awards from the Private Innovate Plan.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Private Innovate Plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted under the Private Innovate Plan during the six months ended June 30, 2022 and 2021. All of the options granted under the Private Innovate Plan are fully vested and as such, there were no stock options vested during the six months ended June 30, 2022. The total fair value of options vested during the six months ended June 30, 2021 under the Private Innovate Plan was approximately $49,000. As of June 30, 2022, there was no unrecognized compensation cost related to unvested stock-based compensation arrangements under the Private Innovate Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Omnibus Incentive Plan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares reserved for issuance under the Omnibus Plan automatically increase on the first day of each calendar year beginning in 2019 and ending in 2022 by an amount equal to the lesser of (i) five percent of the number of shares of common stock outstanding as of December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the immediately preceding calendar year or (ii) such lesser number of shares of common stock as determined by the Board (the “Evergreen Provision”). On January 1, 2022, the number of shares of common stock available under the Omnibus Plan automatically increased by 12,911,771, pursuant to the Evergreen Provision. The Board elected to forgo the increase from the Evergreen Provision that would have increased the option pool by 5% of the shares of common stock outstanding on January 1, 2021. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there were options to purchase 23,885,389 shares of the Company’s common stock outstanding under the Omnibus Plan. The Omnibus Plan expired on April 30, 2022 and no new awards will be granted under the Omnibus Plan but any awards outstanding under the Omnibus Plan will remain subject to the Omnibus Plan. On June 22, 2022, the Company’s stockholders approved the adoption of the 2022 Plan previously approved by the Board. Any shares subject to outstanding awards under the Omnibus Plan that subsequently expire, terminate or are surrendered or forfeited for any reason without issuance of shares will automatically become available for issuance under the 2022 Plan. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used in estimating the fair value of the options granted under the Omnibus Plan using the Black-Scholes option pricing model for the periods presented were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.803%"><tr><td style="width:1.0%"/><td style="width:23.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock-price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> —%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75% - 76%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68% - 85%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—% - —%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 1.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 1.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 6.1 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 6.1 years</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Omnibus Plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,608,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,885,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,208,688 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,774,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted under the Omnibus Plan was $0.51 during the three and six months ended June 30, 2022. The weighted-average grant date fair value of options granted under the Ominbus Plan was </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.26 and $1.66 during the three and six months ended June 30, 2021, respectively. The total intrinsic value of options exercised was approximately $27,000 and $39,000 during the three and six months ended June 30, 2021, respectively. There were no options exercised during the three and six months ended June 30, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of stock option awards vested under the Omnibus Plan was approximately $1.7 million and $2.9 million during the three and six months ended June 30, 2022, respectively. As of June 30, 2022, there was approximately $7.9 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements under the Omnibus Plan. This cost is expected to be recognized over a weighted average period of 3.1 years. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Omnibus Plan provides for accelerated vesting, if approved by the Company’s Board. During the six months ended June 30, 2022, in accordance with the separation and consulting agreement entered into with our former Chief Financial Officer, the Company accelerated the vesting of all remaining unvested options and extended the exercise period to ten years from the issuance date. During the six months ended June 30, 2021, the Board approved the acceleration and extension of unvested options held by a former board member whose term on the Board was expiring. The Company recognized additional non-cash stock compensation expense related to the modifications of $1.1 million during the three and six months ended June 30, 2022 and $0.1 million during the three and six months ended June 30, 2021. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no RSUs granted during the three and six months ended June 30, 2022 and 2021 and there were no unvested RSUs as of June 30, 2022. The Company recognized share-based compensation expense for RSUs of approximately $52,000 and $104,000 during the three and six months ended June 30, 2021, respectively. There was no share-based compensation expense for RSUs during the three and six months ended June 30, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Stock Incentive Plan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Plan was approved by the Company’s stockholders on June 22, 2022. The 2022 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, or other stock awards. Upon adoption of the 2022 Plan, there were 12,000,000 shares of the Company’s common stock reserved for issuance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there were options to purchase 712,545 shares of the Company’s common stock outstanding under the 2022 Plan and 11,287,455 shares available for issuance under the 2022 Plan. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used in estimating the fair value of the options granted under the 2022 Plan using the Black-Scholes option pricing model for the periods presented were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.803%"><tr><td style="width:1.0%"/><td style="width:23.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock-price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the 2022 Plan:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted under the 2022 Plan was $0.18 during the three and six months ended June 30, 2022. There were no options granted under the 2022 Plan during the three and six months ended June 30, 2021. There were no options exercised under the 2022 Plan during the three and six months ended June 30, 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options vested under the 2022 Plan during the three and six months ended June 30, 2022 and 2021. As of June 30, 2022, there was approximately $0.1 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements under the 2022 Plan which is expected to be recognized over a weighted-average period of 3.0 years. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RDD Option Grants</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the RDD Merger Agreement, the Company assumed 1,014,173 option grant agreements awarded to RDD employees upon consummation of the merger with RDD (the “RDD Options”) on April 30, 2020. There were 985,807 RDD Options outstanding as of June 30, 2022 at a weighted-average exercise price of $0.63 per share. All of the RDD Options are fully vested and there were no RDD Options vested during the six months ended June 30, 2022 and 2021. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the RDD Options:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, there were 28,366 options exercised at a weighted-average exercise price of $0.74. The total intrinsic value of RDD Options exercised was approximately $27,000 during the six months ended June 30, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-based Compensation Expense</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<nmtr:NumberOfStockOptionPlans contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNTc_35362450-aeac-4121-947b-32237d34fa8e" unitRef="equity-basedincentiveplan"> 3 </nmtr:NumberOfStockOptionPlans>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i172c545015a041c08606c3a163282a0b_I20200430" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjY1_67463d14-afa2-4d20-af5e-66ed4c44c308" unitRef="shares"> 1014173 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="ic73df32ab27847eebda82c02a48e6a67_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDAw_34a35995-5b83-4f54-97c4-23a284655e50"> P4Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<nmtr:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTerm contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQw_57cf77b3-3afe-4cae-944b-773d922e07cf"> P10Y </nmtr:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTI1OA_f0a3d429-40ea-4b3e-bf15-f8744960e869" unitRef="shares"> 3592248 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQ3Mg_c78b017c-e5ac-488b-a4fb-da49b1a80158">
<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Private Innovate Plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,248 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Omnibus Plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,608,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,885,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,208,688 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,774,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the 2022 Plan:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr></table></div>
</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i57eb1736d8cf4b8ea380b3b967089152_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMS0yLTEtMS0zNDg0NQ_4992b7ee-0a26-4c02-a433-9d77b630f5a1" unitRef="shares"> 5300518 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i57eb1736d8cf4b8ea380b3b967089152_I20211231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMS00LTEtMS0zNDg0NQ_303f3e0c-98c3-427d-95ba-c1147667a361" unitRef="usdPerShare"> 1.69 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i57eb1736d8cf4b8ea380b3b967089152_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMS02LTEtMS0zNDg0NQ_74f9d12c-a5d6-4161-94b6-920f76eb1a7c" unitRef="usd"> 837459 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="ibc1fd82c7be940aab649d2f9faeb2c06_D20210101-20211231" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMS04LTEtMS0zNDg0NQ_ccaeafd4-5454-4f73-ba1d-69bcce643863"> P2Y8M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMi0yLTEtMS0zNDg0NQ_c4fda3f6-ed82-458e-ac0b-b32ea31081e7" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMi00LTEtMS0zNDg0NQ_4206da07-d24b-4655-8bd9-95174baf2548" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMy0yLTEtMS0zNDg0NQ_68b76096-869b-4083-8863-0fc88ef18ac7" unitRef="shares"> 1708270 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfMy00LTEtMS0zNDg0NQ_6c8b607a-68ef-4a26-b8bf-948b0cb2365e" unitRef="usdPerShare"> 2.09 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNC0yLTEtMS0zNDg0NQ_b4957358-37a4-48d2-a601-13f88ceade62" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNC00LTEtMS0zNDg0NQ_7c03cf64-f03f-4ea7-b13f-9a483276d50a" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNS0yLTEtMS0zNDg0NQ_4894995f-e59a-4fa5-aca2-2b0dce933a46" unitRef="shares"> 3592248 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNS00LTEtMS0zNDg0NQ_dceb902c-f2cb-4fc5-b643-a349ede4b6e2" unitRef="usdPerShare"> 1.49 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNS02LTEtMS0zNDg0NQ_0f5cc4f8-db60-4292-99dc-800209ebf98c" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNS04LTEtMS0zNDg0NQ_4d95dc51-46d1-48b2-b2ff-69ff942b1638"> P3Y2M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNi0yLTEtMS0zNDg0NQ_5f0ac17b-f61e-4a17-aeb5-7622df28d88c" unitRef="shares"> 3592248 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNi00LTEtMS0zNDg0NQ_a4b1169e-c1c8-4056-ac6e-db49ade74c6e" unitRef="usdPerShare"> 1.49 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNi02LTEtMS0zNDg0NQ_f0b2ee28-a63d-40a5-88b3-28394dc2e191" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjg0M2Y5ZjQ4ODZkYTQxNjk4MTQ1OTUyNzgwODZlN2MwL3RhYmxlcmFuZ2U6ODQzZjlmNDg4NmRhNDE2OTgxNDU5NTI3ODA4NmU3YzBfNi04LTEtMS0zNDg0NQ_4789ad01-0767-45f7-ab3b-3be91090a873"> P3Y2M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="ia7c98d043f1b43e089c81076d8e158ea_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTU0Nw_9f597ee6-3aa1-4161-84ed-508df11f08ab" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTU0Nw_a05343aa-590b-4bbf-b884-42b59e2949b0" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="i899f048ad1bc4ce28972328b04a2dc09_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njc5OA_fd7c4d72-c08c-4785-9d2b-01e95fce8d5e" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="ia7c98d043f1b43e089c81076d8e158ea_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTY0MDMwNA_cc1624eb-84f7-4099-a890-b4fb9cb5bee6" unitRef="usd"> 49000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i5c230e041e5c4a7ba7acba9c612bebc9_I20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTgwNA_9e9656f0-ae8d-472a-9a92-10c07f9feb40" unitRef="usd"> 0 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNjU3Nw_62ee2c89-c575-4291-9438-454823e38c04" unitRef="number"> 0.05 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="i06d5468f6ab742c4921c6a98667cf93f_D20220101-20220101" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNjkzMA_e73566c5-45b5-466d-bcd0-e9eb015fbf82" unitRef="shares"> 12911771 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="id3ede521a8b540ed87f03eb5d9a0df51_D20210101-20210101" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNzA4Ng_5b422b54-52bb-4b1c-98ce-723b6f4ce560" unitRef="number"> 0.05 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTk4NQ_2d922c9d-2843-413d-b40c-b9b6a61b4596" unitRef="shares"> 23885389 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQ2Ng_02d6b1d5-777c-4ddd-bf0c-04ad8f410f49">
<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used in estimating the fair value of the options granted under the Omnibus Plan using the Black-Scholes option pricing model for the periods presented were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.803%"><tr><td style="width:1.0%"/><td style="width:23.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock-price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> —%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75% - 76%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68% - 85%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—% - —%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 1.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1% - 1.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 6.1 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 6.1 years</span></div></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used in estimating the fair value of the options granted under the 2022 Plan using the Black-Scholes option pricing model for the periods presented were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.803%"><tr><td style="width:1.0%"/><td style="width:23.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock-price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMi0yLTEtMS0zNDg0NQ_d650bc8b-0b07-493a-9525-22932c98c9d0" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMi00LTEtMS0zNDg0NQ_cba8fde7-ab10-4ecd-98ca-a4d861c878a7" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMi02LTEtMS0zNDg0NQ_65c47738-60e3-44d3-a640-193689ea32c6" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMi04LTEtMS0zNDg0NQ_74ac9b75-5174-4a8a-aadf-5bf89122d965" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy0yLTEtMS0zNDg0NS90ZXh0cmVnaW9uOmZmZWQzNzQ3MmQxNTQ0MmY4Y2UxZGUyZjEzMGEyM2Y5XzU_99631801-0ac7-4f21-a2b4-5dd54d130b49" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmM1ZjEwNjAyYjQzMDQ0NmU4MDY0MjllYzg2OWJlYTliXzQ_a8d7f4ee-4fc4-4770-a380-593064889786" unitRef="number"> 0.75 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmM1ZjEwNjAyYjQzMDQ0NmU4MDY0MjllYzg2OWJlYTliXzk_6198bd0b-bb9a-4813-a098-152169c19b8f" unitRef="number"> 0.76 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy02LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmFiNzJjODI2OTMxMDQ0ZTU4MTE4YzUzNWExZDg2MjU1Xzk_1e9fd1df-8702-4889-bc65-561eab0fb892" unitRef="number"> 0.79 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjlhYTA5MWE0NjQwZjRjMzdhY2U3ZWJlYmQzZTZiZjkzXzQ_dd1ceaa0-1aba-4278-9638-98cfc5a13617" unitRef="number"> 0.68 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfMy04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjlhYTA5MWE0NjQwZjRjMzdhY2U3ZWJlYmQzZTZiZjkzXzk_92a75796-3d17-4472-9e0e-cba56d3b3539" unitRef="number"> 0.85 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC0yLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjA5Zjk1ZmFlOTUyMjQ3ODRhMDg3ZDNhNDhkYjgzNTgyXzQ_4f9304d3-87d6-45ef-983d-52b2124ac134" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC0yLTEtMS0zNDg0NS90ZXh0cmVnaW9uOjA5Zjk1ZmFlOTUyMjQ3ODRhMDg3ZDNhNDhkYjgzNTgyXzk_24470472-c803-456f-9402-e72f75b8e0cd" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmY4NzY0MWNiOWQwOTRlMmY4YWY3M2QzM2U2NGZjNDIzXzQ_efe6e3d6-020e-4a3e-ac14-8a2c6cfacf09" unitRef="number"> 0.008 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmY4NzY0MWNiOWQwOTRlMmY4YWY3M2QzM2U2NGZjNDIzXzk_fbfe3427-9bf0-4fd2-bbae-7fdfd90a92cd" unitRef="number"> 0.011 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC02LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjVkNTNjNDVmMTBhZDQ3YmViY2E0OWMyNWJlN2ZmMzFiXzQ_cc92e526-334d-4ca9-b507-ba120a920d47" unitRef="number"> 0.014 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC02LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjVkNTNjNDVmMTBhZDQ3YmViY2E0OWMyNWJlN2ZmMzFiXzk_0566d23b-88bb-49d8-976a-aee31b7ecbb4" unitRef="number"> 0.019 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmIzMTliNmIyYTRkZDRiZjViYjM0NTFlOTE5MGRmNWE5XzQ_d575925c-b1b1-4a06-9674-705dd5f697f4" unitRef="number"> 0.001 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNC04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOmIzMTliNmIyYTRkZDRiZjViYjM0NTFlOTE5MGRmNWE5Xzk_ce0a4c82-8de4-447b-9eed-432a544be291" unitRef="number"> 0.011 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="i82528eda4fa54d6999a3741878b8bc4a_D20210401-20210630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNS00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjc3NjRmOTU1ZmEzYzRkMWU5YzhmZWY3ODg5NTdmODFlXzQ_20c92bc6-2ced-4dcb-9a04-478d0cde08d9"> P2Y3M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="id811568b4e844937b524098c0ec2c421_D20210401-20210630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNS00LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjc3NjRmOTU1ZmEzYzRkMWU5YzhmZWY3ODg5NTdmODFlXzk_17f47c66-ad14-43f0-92bb-e1c9b178fd98"> P6Y1M6D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNS02LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjQ1ZTRiYWJiZTBhMjQ2ZDk5NzkzZTY0MDQxYWYzYzM5Xzk_834bb237-b09b-47e2-a1c8-baecfd74390e"> P6Y1M6D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="ia942ac784750472cb192fa90ff75692a_D20210101-20210630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNS04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjRhOThlZDM2ZDE3MDRiNTFiZGRjOTEzZjYxY2ExYWZhXzQ_94453f65-e43e-40bb-8a5c-dea6a3c03882"> P2Y3M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="ib97914b7aeb54e318a556b53c46cc806_D20210101-20210630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjM5NDM2Y2E1YTEyZjRmN2Q5MTMxZGYzOTNhN2U0NmE2L3RhYmxlcmFuZ2U6Mzk0MzZjYTVhMTJmNGY3ZDkxMzFkZjM5M2E3ZTQ2YTZfNS04LTEtMS0zNDg0NS90ZXh0cmVnaW9uOjRhOThlZDM2ZDE3MDRiNTFiZGRjOTEzZjYxY2ExYWZhXzk_e36a2982-fdac-4ba9-8dd6-dbb6f60695f3"> P6Y1M6D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i91fe66d5522a44a0bb2965da5556ff9d_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMS0yLTEtMS0zNDg0NQ_9f690aab-6c97-4f1b-b077-59701325ab9e" unitRef="shares"> 14608442 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i91fe66d5522a44a0bb2965da5556ff9d_I20211231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMS00LTEtMS0zNDg0NQ_3a06cf5d-39be-4cdd-8326-ec4865422740" unitRef="usdPerShare"> 1.19 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i91fe66d5522a44a0bb2965da5556ff9d_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMS02LTEtMS0zNDg0NQ_d788f978-a899-4290-958f-4b219c27e4c8" unitRef="usd"> 2296720 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="i1e6759684bba42dc91d0c9397ca4db5b_D20210101-20211231" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMS04LTEtMS0zNDg0NQ_300f2966-2efe-4c7a-a9df-2a677e1cdc0f"> P8Y6M </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMi0yLTEtMS0zNDg0NQ_ce63d071-dd4e-4c34-bd02-2567a88567ad" unitRef="shares"> 9412420 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMi00LTEtMS0zNDg0NQ_cbac0a46-0a0f-4127-8086-56501ebf1d72" unitRef="usdPerShare"> 0.74 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMy0yLTEtMS0zNDg0NQ_3cde1f9e-2ad7-4193-9af8-2e4a8e38081c" unitRef="shares"> 135473 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfMy00LTEtMS0zNDg0NQ_f39a7de3-b332-4082-ad63-7ec49f99f02d" unitRef="usdPerShare"> 0.75 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNC0yLTEtMS0zNDg0NQ_8870e467-c70a-4c98-82f1-3da2a1ed4d99" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNC00LTEtMS0zNDg0NQ_29341aeb-991d-4f12-9058-14f7a155eefe" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNS0yLTEtMS0zNDg0NQ_28a640fd-3121-4dd8-b0be-a2a74f36489f" unitRef="shares"> 23885389 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNS00LTEtMS0zNDg0NQ_de3cc303-9357-4413-afb3-64477b03a71a" unitRef="usdPerShare"> 1.01 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNS02LTEtMS0zNDg0NQ_cebfca8d-c9c9-407c-bd99-5a56ef06e461" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNS04LTEtMS0zNDg0NQ_106429ca-5590-4985-8044-2a4000f3fc2a"> P8Y8M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNi0yLTEtMS0zNDg0NQ_09074ba0-7b4e-4f86-8f29-5f601ecef356" unitRef="shares"> 9208688 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNi00LTEtMS0zNDg0NQ_95e1b63b-64da-46e7-a3a8-3c8e6ce9752d" unitRef="usdPerShare"> 1.20 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNi02LTEtMS0zNDg0NQ_777cec93-2392-4170-adf4-8289eae8da21" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNi04LTEtMS0zNDg0NQ_e4980003-3772-40a4-b3a6-d4e8da6c2289"> P7Y9M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNy0yLTEtMS0zNDg0NQ_b71975b9-6dfb-42e5-a13e-5a5eeeaf7208" unitRef="shares"> 22774801 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNy00LTEtMS0zNDg0NQ_6f0d6f01-ec2f-4e90-86b7-1f0b7093963d" unitRef="usdPerShare"> 1.02 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNy02LTEtMS0zNDg0NQ_d1511784-e8c0-46c4-bc33-8f4d44d720d6" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOmE5YjgzYTFlMzYxYTRiOTM4MGFjOWNjOGJkMmYxYTY4L3RhYmxlcmFuZ2U6YTliODNhMWUzNjFhNGI5MzgwYWM5Y2M4YmQyZjFhNjhfNy04LTEtMS0zNDg0NQ_74ba6299-2224-4813-be45-795f5e486146"> P8Y7M6D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjQ5Ng_9b567f41-f2c8-460f-a051-56ed34dd8282" unitRef="usdPerShare"> 0.51 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjQ5Ng_d2e7c274-61f4-434a-af07-2e9f2b1fd951" unitRef="usdPerShare"> 0.51 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjUwMw_d0247871-7cac-4f2b-a103-e54b04e0cfeb" unitRef="usdPerShare"> 1.26 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNTQzNw_02d93947-b422-4076-b37c-59cb2041dbbb" unitRef="usdPerShare"> 1.66 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjYyNQ_f2136b00-57b1-40ab-a128-d9954314b2b7" unitRef="usd"> 27000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNTQ3Mg_f53d12d3-1d8e-4398-9870-ebf8fcd544c9" unitRef="usd"> 39000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjY4NQ_a1a7dcfb-5c7a-4aae-a635-8c51cca568f2" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjY4NQ_dc98b80a-8667-49f9-8634-43e6257a2f47" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjg0NA_95b1ded5-e0db-430d-8f19-98b6efdf500d" unitRef="usd"> 1700000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjg1MQ_aa42a07c-daf0-423c-b0d3-f63a85d01d3b" unitRef="usd"> 2900000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i5a440305ac384b5aac5312cd56e22bf9_I20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjkyNg_0241f721-5fa5-48b5-a183-6728838ae51e" unitRef="usd"> 7900000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzEyNA_121042c4-3a7e-497f-bb2f-f8b54e918562"> P3Y1M6D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="i4e08de7aebc245afbc59ca2b5f28e190_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzMzg5Nw_84c5b8ef-57bc-4766-9b16-2d4b405c3f99"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensation contextRef="i037972aec0c743bca8e2946c04e221f2_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTY0MDMyMg_31535472-c883-4092-8ac2-eff9a0dc3b1c" unitRef="usd"> 1100000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="i3c7f6184883c41fb92bb5068c4b68710_D20220401-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTY0MDMyMg_5e34f8ee-6a14-4d7e-a21b-bc7f99be2226" unitRef="usd"> 1100000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="ia17687cc15434372bfe0b869d5ad6a6e_D20210101-20210630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgwMw_442b38e8-14b2-428d-9b0c-8cf9815e833d" unitRef="usd"> 100000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="iefb44601fd544951b828dc05536a64ba_D20210401-20210630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgwMw_c3c2b610-c4b9-4973-9925-9edeca41cac3" unitRef="usd"> 100000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="iedc2390d12d84492ba74d904c0daaeb5_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzE0MQ_37faadd6-46e0-4ed8-9042-8182b9d2fd44" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="iec3ac3d6c4d54d75baec3438a8dc85d2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzE0MQ_3e142b98-e759-4b61-9e21-6d22e8888526" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="i26d540e0d0734383af294884934fe325_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzE0MQ_ca81b7e8-e54b-43c1-a7af-fc7ef73c2ad1" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="icf8daca992f448fbbcd475fa2dd983ad_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzE0MQ_d6e5023e-6658-44a4-81f6-5a525b263fa6" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="i65a0a15ddc0c4991b23c9efc7e389b37_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgyMA_179a2e60-6689-42ef-8844-243c3923c9df" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="iedc2390d12d84492ba74d904c0daaeb5_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzM0NA_825e8d44-d11a-4b21-beab-4560e8a9a7fa" unitRef="usd"> 52000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i26d540e0d0734383af294884934fe325_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzNDEwOA_a34caded-f086-4a0a-b86c-194eb1de9ab6" unitRef="usd"> 104000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="iec3ac3d6c4d54d75baec3438a8dc85d2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzQwNg_351bc8a9-5b35-4a28-b1f6-48205c17e306" unitRef="usd"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="icf8daca992f448fbbcd475fa2dd983ad_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzQwNg_d1ad6fff-0740-4e7c-8943-987cedcbc239" unitRef="usd"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i93e7bcd2b8024c0fbcdbe6f410651dfe_I20220622" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njg1MQ_6f6b5472-d0e7-4750-9d15-879cb62e0e44" unitRef="shares"> 12000000 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTUzMw_f8230654-4521-4249-963f-c9fcaacf5853" unitRef="shares"> 712545 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTUzOA_a6b4140f-53a9-4ed9-8c90-49a621438ebd" unitRef="shares"> 11287455 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMi0yLTEtMS0zNTUwMg_16daa36b-5710-4786-ae94-b5aa50c44015" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="idb705766e14544f8aef78c1869705805_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMi00LTEtMS0zNTUwMg_77d21814-161c-4578-8a9b-d905c122cad2" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMi02LTEtMS0zNTUwMg_5e15cb2b-476a-4a0c-abe4-e8aba67297f5" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMi04LTEtMS0zNTUwMg_25c33974-1cc3-4697-ad33-d7381bc38f66" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMy0yLTEtMS0zNTUwMg_08c320ab-8721-4476-9044-9412532ecf4d" unitRef="number"> 0.79 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="idb705766e14544f8aef78c1869705805_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMy00LTEtMS0zNTUwMg_d8730aa2-20f0-4540-a58b-29c2292a3da2" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMy02LTEtMS0zNTUwMg_c72f7759-54fc-4403-8921-faedd9914e9a" unitRef="number"> 0.79 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfMy04LTEtMS0zNTUwMg_22b00f6d-840c-4167-86b2-22242758fbf2" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNC0yLTEtMS0zNTUwMg_5e8c2c2f-c0a5-40ec-a5df-268d504faeda" unitRef="number"> 0.032 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="idb705766e14544f8aef78c1869705805_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNC00LTEtMS0zNTUwMg_0bd64b75-1db6-4b82-a871-aee44d29fd28" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNC02LTEtMS0zNTUwMg_8dcd7307-c162-4ad4-a104-2ae487f08c3e" unitRef="number"> 0.032 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNC04LTEtMS0zNTUwMg_9552d066-3a19-4c53-8dbf-f852e5ab4669" unitRef="number"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNS0yLTEtMS0zNTUwMg_87251a14-7d96-4aa5-80be-14d87cc14724"> P5Y9M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjRjYzYyYmUxNjY3NDQ3Y2U4ZTBkYjk1ZTQ5YjE0MDc0L3RhYmxlcmFuZ2U6NGNjNjJiZTE2Njc0NDdjZThlMGRiOTVlNDliMTQwNzRfNS02LTEtMS0zNTUwMg_a118fce8-bc8f-44d0-98b3-d230d8cb5cf7"> P5Y9M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i71ca31d8ff2b41d9acab4d38e431d956_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMS0yLTEtMS0zNjc1OQ_d50e4a52-4007-4f99-800b-280ddd6f3c3d" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i71ca31d8ff2b41d9acab4d38e431d956_I20211231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMS00LTEtMS0zNjc1OQ_72c9d383-5465-4b55-af2b-57025e829d33" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i71ca31d8ff2b41d9acab4d38e431d956_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMS02LTEtMS0zNjc1OQ_235b6558-0ea0-4c32-ba5f-65c66bc5d057" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMi0yLTEtMS0zNjc1OQ_7bebf616-8256-4370-a3a5-943f1a6e706a" unitRef="shares"> 712545 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMi00LTEtMS0zNjc1OQ_de152ef3-4e14-40f5-8073-43b84cbf40d5" unitRef="usdPerShare"> 0.26 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMy0yLTEtMS0zNjc1OQ_a7866416-1445-4ad0-ae47-77b196f3610f" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfMy00LTEtMS0zNjc1OQ_6aaa4cfe-9641-4da8-9894-d011bc7cf725" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNC0yLTEtMS0zNjc1OQ_fdcca89d-9bda-45a4-9895-2f6c311c1c68" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNC00LTEtMS0zNjc1OQ_51fd051d-c57f-45d9-a4d5-b637c70f39b5" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNS0yLTEtMS0zNjc1OQ_f8230654-4521-4249-963f-c9fcaacf5853" unitRef="shares"> 712545 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNS00LTEtMS0zNjc1OQ_4ea2158d-f6e7-45ba-9a8e-21b210d4a1c7" unitRef="usdPerShare"> 0.26 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNS02LTEtMS0zNjc1OQ_68bd26c9-21a1-475f-a88f-2e0206527dbb" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNS04LTEtMS0zNjc1OQ_37efe3b2-9712-4960-b211-b2b60dc8370e"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNi0yLTEtMS0zNjc1OQ_33aeb5a8-f3b0-4374-978c-16e035733cf8" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNi00LTEtMS0zNjc1OQ_5213771a-a4b0-4426-923b-c7b6c0d91360" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNi02LTEtMS0zNjc1OQ_5b5af898-4046-486d-83cb-2ace0a6a4d7e" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNy0yLTEtMS0zNjc1OQ_60929824-99e2-4f0e-8482-53ad410bccce" unitRef="shares"> 659601 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNy00LTEtMS0zNjc1OQ_45faf88d-c2e2-4927-afd6-996bb79fae9a" unitRef="usdPerShare"> 0.26 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNy02LTEtMS0zNjc1OQ_b55cfc83-3ad2-498d-9cfb-89d54148048c" unitRef="usd"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjAzM2E4NmYyNTdmYzRhZDdiNjRlOGY0NTNlZmNmYmY0L3RhYmxlcmFuZ2U6MDMzYTg2ZjI1N2ZjNGFkN2I2NGU4ZjQ1M2VmY2ZiZjRfNy04LTEtMS0zNjc1OQ_e66cd411-a6db-4205-a184-55f7e19d97f7"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTA4OQ_05385884-1782-48a8-9f4c-b99254ae1469" unitRef="usdPerShare"> 0.18 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTA4OQ_30383ad2-730b-48ad-86b7-0b564a939bb6" unitRef="usdPerShare"> 0.18 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgzMA_3256d6cd-ea11-4a73-90e6-394bd8ba4ffd" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="idb705766e14544f8aef78c1869705805_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgzMA_a66d3fcf-e4e1-4c5a-916e-6f29d6ddbd7b" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgzOA_3ee70239-7155-4bad-8ad8-4f9dfbd0bdce" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2NjgzOA_62c41d1a-5180-4320-8baf-b735838526d1" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="i84d9d55762eb430d868059eb472ab4b2_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njg0Ng_16e8e0e7-2df5-45ac-ba12-a670c203c022" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="idb705766e14544f8aef78c1869705805_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njg0Ng_63187a13-f3b0-414c-a139-66901b929f02" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="i34861c5c3d1b476ea8903fa8af84b7f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njg0Ng_f353191b-5b5b-47cf-b2d7-ed8b5688a371" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMjE5OTAyMzI2Njg0Ng_ff969eb7-0b4e-477e-831a-637173a286d2" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="ia089f8846b9d4c19968bbeeb8ebe401f_I20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTA5OQ_010d9a57-b0c1-4284-97b9-42c9f5002b57" unitRef="usd"> 100000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="ied0728b29d464b37b19c609377f024f0_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMTA5OTUxMTYzOTEyNA_aea8d623-2477-47b0-8248-b5c309ddebb6"> P3Y </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i172c545015a041c08606c3a163282a0b_I20200430" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzU3NQ_67463d14-afa2-4d20-af5e-66ed4c44c308" unitRef="shares"> 1014173 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzcxMw_9aa14bf9-a6e1-4b9e-936c-aa77b8d89b6a" unitRef="shares"> 985807 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzgwMQ_c69b5f64-fcb6-4076-b6b1-6fc7c62f2821" unitRef="usdPerShare"> 0.63 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzg3MA_9384ebf7-0b5b-49f9-b6f5-589f0692de02" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="i562ff4c2ad8a4b0eaafc4a332fa277db_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfMzg3MA_e3231e22-8a4b-4d59-ac77-06c8ddc71c0c" unitRef="shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQ2Mw_8a068906-86ef-4c9b-80b2-5ab8946a5e07">
<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the RDD Options:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,807 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="idc1585f8ea074a6488cbec7657fa7d0f_I20211231" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMS0yLTEtMS0zNDg0NQ_73797139-b1cc-4458-90fb-0cef5ec4fa6b" unitRef="shares"> 985807 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="idc1585f8ea074a6488cbec7657fa7d0f_I20211231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMS00LTEtMS0zNDg0NQ_dc523cf2-45e4-490f-8ca5-43b5446f7110" unitRef="usdPerShare"> 0.63 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="idc1585f8ea074a6488cbec7657fa7d0f_I20211231" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMS02LTEtMS0zNDg0NQ_952c643e-4c4c-4acf-8935-1d438acbbe4c" unitRef="usd"> 343486 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="ica711ac772b04e35b3499b247062e197_D20210101-20211231" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMS04LTEtMS0zNDg0NQ_5cd64633-bee5-4025-b74f-290aba5eb88c"> P3Y3M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMi0yLTEtMS0zNDg0NQ_d80a5408-010a-49f5-8368-09a358c62dfa" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMi00LTEtMS0zNDg0NQ_5702d1ed-3aaa-4e69-aa26-ec11d8f88ec8" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMy0yLTEtMS0zNDg0NQ_46657117-b403-47cf-8813-2642b0bd5724" unitRef="shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfMy00LTEtMS0zNDg0NQ_6a575bc0-7fb1-40b2-ae4f-f99504f09824" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNC0yLTEtMS0zNDg0NQ_26bc8a82-6254-49c8-aad7-3ce5c8a73ca0" unitRef="shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNC00LTEtMS0zNDg0NQ_0ab0139c-e162-47ac-9ec9-cc90ea24de59" unitRef="usdPerShare"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNS0yLTEtMS0zNDg0NQ_755f768a-9bde-46cd-9461-a3281e7651f4" unitRef="shares"> 985807 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNS00LTEtMS0zNDg0NQ_de0ddee0-d2d0-430f-95f0-eb566f94fbf0" unitRef="usdPerShare"> 0.63 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNS02LTEtMS0zNDg0NQ_0c59be28-0988-428e-aaf8-814604b71f04" unitRef="usd"> 37416 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNS04LTEtMS0zNDg0NQ_ae405479-2b66-479c-9d2b-4e0d95e95388"> P2Y9M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNi0yLTEtMS0zNDg0NQ_505bd367-bebc-41e8-86db-63e6bd8b4c69" unitRef="shares"> 985807 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNi00LTEtMS0zNDg0NQ_b6ba0aa4-13b7-4dd6-a04f-038a8e296403" unitRef="usdPerShare"> 0.63 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="i31159c63fe234ee28d3f55c6fbff574a_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNi02LTEtMS0zNDg0NQ_a0af330d-73f6-4399-809e-75a75402fead" unitRef="usd"> 37416 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="i34c39e5fba97462a88eb6a7cb05e48c2_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjdhY2U1NmExYTdkODQwNTVhODkxN2U4NmFiNTBjOTU1L3RhYmxlcmFuZ2U6N2FjZTU2YTFhN2Q4NDA1NWE4OTE3ZTg2YWI1MGM5NTVfNi04LTEtMS0zNDg0NQ_6bca3e1e-a57e-4931-9c65-e07ea22466ac"> P2Y9M18D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="i562ff4c2ad8a4b0eaafc4a332fa277db_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDA4NQ_d0a85cb3-9a43-43bc-aeec-0885db7181b8" unitRef="shares"> 28366 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="i562ff4c2ad8a4b0eaafc4a332fa277db_D20210101-20210630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDE0Ng_4831389e-cc34-4ba0-8637-7c99f58a2564" unitRef="usdPerShare"> 0.74 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="i562ff4c2ad8a4b0eaafc4a332fa277db_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDIxOQ_ed9c55c7-cce3-4e36-95c0-756c8b4e1097" unitRef="usd"> 27000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RleHRyZWdpb246ZDI4NGFjNTg4NjJmNGFlMjllZTFjZmFmNzQ1NjdmNzRfNDQ2OQ_7d378c10-16b3-4479-97a5-cbc32945c419">
<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense recognized in the accompanying condensed consolidated statements of operations and comprehensive loss was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,464,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div>
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i0bc0477f0ff4420598406fa5ca5c002d_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMi0yLTEtMS0zNDg0NQ_53955af4-7918-4f95-9b02-028b38bf6ea3" unitRef="usd"> 248000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="iac4cc2ff191c44a8b90c08111ea71239_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMi00LTEtMS0zNDg0NQ_ad371536-58f1-4ca5-9b0f-f1a30ec6af2b" unitRef="usd"> 280000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i65a1e1d787cb4d45b03e28d732eeb37e_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMi02LTEtMS0zNDg0NQ_a5353caa-ac7a-4b61-ab71-7336a843c90e" unitRef="usd"> 426000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i91ce303423f340ae903472ec1fff6018_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMi04LTEtMS0zNDg0NQ_4448dad4-3360-44bf-81be-190e6559ffd7" unitRef="usd"> 442000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="ie0f9f046f56942218c833782de58823c_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMy0yLTEtMS0zNDg0NQ_87de3e7d-6fdd-46fa-92f7-117fd57e07a9" unitRef="usd"> 1526000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="ic514e4e58330400e8e66a43125acf1bb_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMy00LTEtMS0zNDg0NQ_69a3b5cf-190c-4da7-abb4-7b56b73a6d03" unitRef="usd"> 657000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="icb0bb2e204cd42ad85dcfde88fd781c2_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMy02LTEtMS0zNDg0NQ_2f69ebbf-b8bf-41ef-a1fd-95326f405469" unitRef="usd"> 2038000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i0b54ca0f248c4c2180a64a364ba47626_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfMy04LTEtMS0zNDg0NQ_dbd87ff7-ac42-4a1d-8206-42bd20308f92" unitRef="usd"> 917000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfNC0yLTEtMS0zNDg0NQ_942e39ff-35e4-493a-b6f9-80ab0d7bf690" unitRef="usd"> 1774000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfNC00LTEtMS0zNDg0NQ_0c6486d2-3f5d-49c1-b284-d35d94dc4b65" unitRef="usd"> 937000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfNC02LTEtMS0zNDg0NQ_bdf6a531-6214-465c-9df3-f74289edee05" unitRef="usd"> 2464000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81NS9mcmFnOmQyODRhYzU4ODYyZjRhZTI5ZWUxY2ZhZjc0NTY3Zjc0L3RhYmxlOjk0ZDRhYmQ4NWYxZjRiMDdhMGZiOTNhZDU2MTQ2NjY2L3RhYmxlcmFuZ2U6OTRkNGFiZDg1ZjFmNGIwN2EwZmI5M2FkNTYxNDY2NjZfNC04LTEtMS0zNDg0NQ_437f6028-7c0b-4ff1-9118-8d784298364b" unitRef="usd"> 1359000 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMzY2Mw_9f115af2-72e8-4322-a1a7-6a14f56db35e">
COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into executive employment agreements with the executives (the “Executive Employment Agreements”). The Executive Employment Agreements provide an annual base salary and the opportunity to participate in the Company’s equity compensation, employee benefit and bonus plans once they are established and approved by the Board. The Executive Employment Agreements contain severance provisions if such executive is terminated under certain conditions that would provide the executive with up to 12 months of their base salary and up to 12 months of continuation of health insurance benefits. Additionally, if the Company’s Chief Executive Officer is terminated under certain conditions or resigns for good reason within 12 months of a “change in control,” the Chief Executive Officer will be eligible to receive 18 months of his then-current salary, the amount of his target year-end annual non-equity incentive award, and accelerated vesting of all of his unvested options and restricted stock unit awards.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company enters into separation and general release agreements with former executives of the Company that include separation benefits consistent with the former executives’ employment agreements. There was no severance expense recognized during the three and six months ended June 30, 2022 and 2021. The accrued severance obligation was approximately $0.2 million and $0.4 million as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Lease</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a 4-year lease for office space that expires on September 30, 2024. Base annual rent is $72,000, or $6,000 per month. Monthly payments of $6,000 are due and payable over the 4-year term. The lease contains a 3-year renewal option. The Company recorded a right of use asset of $233,206 and an operating lease liability of $233,206 at the inception of the lease in July 2020. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the present value of the lease payments over the remaining term of the leases using a discount rate of 12%, which represented the Company’s estimated incremental borrowing rate. The renewal options were excluded from the lease payments as the Company concluded the exercise of the option was not considered reasonably certain. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost under ASC 842 was approximately $18,000 for the three months ended June 30, 2022 and 2021, and $36,000 for the six months ended June 30, 2022 and 2021. Operating lease cost is included in general and administrative expenses on the accompanying condensed consolidated statement of operations and comprehensive loss. The total cash paid for amounts included in the measurement of the operating lease liability and reported within operating activities was less than $0.1 million during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Company’s lease liability were as follows: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.035%"><tr><td style="width:1.0%"/><td style="width:75.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.736%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payment </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict; therefore, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<nmtr:SeveranceProvisionsAnnualBaseSalaryPeriod contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfNTgy_c3d98a18-5e5a-43a1-94d9-4dbbac4fca3e"> P12M </nmtr:SeveranceProvisionsAnnualBaseSalaryPeriod>
<nmtr:SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfNjE2_12f49ce2-7cb4-4da8-ba14-b5fc3f0b6605"> P12M </nmtr:SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod>
<nmtr:SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfODg1_c683317b-7831-45a2-b48a-29d08c1fa1ca"> P18M </nmtr:SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod>
<us-gaap:SeveranceCosts1 contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTI5OA_181f746e-950a-45c6-8891-da62b75f6237" unitRef="usd"> 0 </us-gaap:SeveranceCosts1>
<us-gaap:SeveranceCosts1 contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTI5OA_79efb72a-6523-4bf4-b23c-9df001394693" unitRef="usd"> 0 </us-gaap:SeveranceCosts1>
<us-gaap:SeveranceCosts1 contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTI5OA_d2d6052c-8505-41ae-b3b2-e3ac2cdb955a" unitRef="usd"> 0 </us-gaap:SeveranceCosts1>
<us-gaap:SeveranceCosts1 contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTI5OA_ed2474d7-e95f-45d6-9512-59c42771c99c" unitRef="usd"> 0 </us-gaap:SeveranceCosts1>
<nmtr:DeferredCompensationLiabilitySeveranceAccrual contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTQzNg_dede66f9-6038-453a-8f75-05041114f92b" unitRef="usd"> 200000 </nmtr:DeferredCompensationLiabilitySeveranceAccrual>
<nmtr:DeferredCompensationLiabilitySeveranceAccrual contextRef="i10faeb84174c4fdfb2dba438580ab194_I20211231" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTQ0Mw_8a253925-d463-4c9c-b470-e72ff7b0b18c" unitRef="usd"> 400000 </nmtr:DeferredCompensationLiabilitySeveranceAccrual>
<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="i7578ca356aa5434590037bb60026cf65_I20200731" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMzY1OQ_84e9ce19-f059-4c31-909c-267ac832b3c6"> P4Y </us-gaap:LesseeOperatingLeaseTermOfContract>
<nmtr:OperatingLeaseAnnualRentalPayments contextRef="i5fbabc2e5ed54b499a13df6672bd1510_D20200701-20200731" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTY0OQ_14b8d6aa-d8fc-4d86-81f2-e7aef311a968" unitRef="usd"> 72000 </nmtr:OperatingLeaseAnnualRentalPayments>
<nmtr:OperatingLeaseMonthlyRentalPayments contextRef="i5fbabc2e5ed54b499a13df6672bd1510_D20200701-20200731" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTY1Ng_0e944a9b-f524-4cd8-b304-f3692e59e5aa" unitRef="usd"> 6000 </nmtr:OperatingLeaseMonthlyRentalPayments>
<nmtr:OperatingLeaseMonthlyRentalPayments contextRef="i5fbabc2e5ed54b499a13df6672bd1510_D20200701-20200731" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTY5MA_7faf9a46-0676-4e2a-9741-135b50d068e4" unitRef="usd"> 6000 </nmtr:OperatingLeaseMonthlyRentalPayments>
<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="i7578ca356aa5434590037bb60026cf65_I20200731" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMzY2MA_e3523df7-0e38-4a33-a71a-19b6b50e54f1"> P4Y </us-gaap:LesseeOperatingLeaseTermOfContract>
<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="i7578ca356aa5434590037bb60026cf65_I20200731" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMzY2MQ_ed7bcde4-8213-49bf-84ea-037f3fcaaa48"> P3Y </us-gaap:LesseeOperatingLeaseRenewalTerm>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="i7578ca356aa5434590037bb60026cf65_I20200731" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTgyNg_2ba023a9-ce31-4cf1-926d-90107871352a" unitRef="usd"> 233206 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability contextRef="i7578ca356aa5434590037bb60026cf65_I20200731" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTg2NQ_2ed77d25-541d-4d92-a03f-731dcdc2be95" unitRef="usd"> 233206 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMjAzOQ_ab9a952e-71c4-4741-96ad-8f3659666812" unitRef="number"> 0.12 </us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseCost contextRef="ic44b1ef3cdca4e1489779d6271c2c3a6_D20210401-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMjMxNg_4fc9462c-3af0-4d53-9526-a15ad9ae5082" unitRef="usd"> 18000 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="i2d543738fcbd48c882b6a8dadb3ba027_D20220401-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMjMxNg_e48a365c-224d-4e62-a393-c989772c7472" unitRef="usd"> 18000 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="i1b233687e104409199f09bb159ce94f3_D20210101-20210630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTA5OTUxMTYzMTUxNg_a1baf99e-3fc1-4e07-b7be-bbd7e35d2333" unitRef="usd"> 36000 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="-3" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMTA5OTUxMTYzMTUxNg_ca403076-050c-439c-8410-8aa6429adb12" unitRef="usd"> 36000 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeasePayments contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" decimals="-5" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMjY4Mg_18312da9-f726-47ec-ae83-3eb70cd3e84a" unitRef="usd"> 100000 </us-gaap:OperatingLeasePayments>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RleHRyZWdpb246NGQ2MWE0MTgzYzM4NDJlYjgzMzU4NWFjMDMwZGU2MTdfMzY2Mg_4464c312-bc62-4894-8be0-c75827b1b615">
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Company’s lease liability were as follows: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.035%"><tr><td style="width:1.0%"/><td style="width:75.064%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.736%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payment </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfMS0xLTEtMS0zNDg0NQ_f3419acd-0f27-4ff7-b655-d4adf0c432b3" unitRef="usd"> 36000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfMi0xLTEtMS0zNDg0NQ_cc55dc16-bb7b-4b89-a483-6d635be10307" unitRef="usd"> 72000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfMy0xLTEtMS0zNDg0NQ_753ea02d-3d40-46b2-9fbe-ad8905fd6cf6" unitRef="usd"> 54000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfNC0xLTEtMS0zNDg0NQ_48c9ac0c-ef81-408f-b8fd-978dee87593b" unitRef="usd"> 162000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfNS0xLTEtMS0zNDg0NQ_124b55ae-432a-4988-8994-cff1fcd64b5e" unitRef="usd"> 20643 </us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability contextRef="ic4b01d20ffbe4992b77f14dc9ce9885b_I20220630" decimals="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl81OC9mcmFnOjRkNjFhNDE4M2MzODQyZWI4MzM1ODVhYzAzMGRlNjE3L3RhYmxlOmYxNmI1NmMwOGUzZDQ3YTJhMmEyZDY5NTEzNDNiNTI0L3RhYmxlcmFuZ2U6ZjE2YjU2YzA4ZTNkNDdhMmEyYTJkNjk1MTM0M2I1MjRfNi0xLTEtMS0zNDg0NQ_7ad20d10-81a1-4f73-8e30-273041bea503" unitRef="usd"> 141357 </us-gaap:OperatingLeaseLiability>
<us-gaap:SubsequentEventsTextBlock contextRef="i88973275b5234dceb0d2d66e3e9462e4_D20220101-20220630" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMzc5Nw_a4b9f7a6-15de-415f-8d93-9bee3cca3d44">
SUBSEQUENT EVENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Convertible Note</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the purchase of senior secured convertible notes with an institutional investor (the “Holder”). The principal amount of the initial note issued on July 15, 2022 and maturing July 1, 2025, is $21.0 million (the “2022 Convertible Note”), with an option for the Company to issue additional convertible notes to the Holder with principal amounts of up to an aggregate of $70.0 million, subject to certain limitations. The 2022 Convertible Note bears interest equal to the three-month benchmark rate plus 5% (with a floor of 6% and 18% upon default). The 2022 Convertible Note will rank senior to all outstanding and future indebtedness of the Company and its subsidiaries. The 2022 Convertible Note also contains customary affirmative and negative covenants, including limitations on incurring additional indebtedness, the creation of additional liens on the Company’s assets, and entering into investments, as well as a subsequent financing requirement to raise at least $25.0 million by March 31, 2023, and a minimum liquidity requirement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first 12 months following closing, the Company will make interest payments to the Holder but is not required to make any principal payments on the 2022 Convertible Note. The 2022 Convertible Note will be optionally convertible by the Company or the Holder, subject to certain limitations. The Company can elect to make principal or interest payments (or accelerated payments) in common stock instead of cash. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Larazotide Phase 3 Trial in Celiac Disease</span></div>On August 15, 2022, the Company announced the decision to discontinue further development of larazotide in celiac disease. In connection with the discontinuation of the celiac disease clinical trial program, the Company plans to reallocate financial resources and support behind the vurolenatide SBS Phase 3 program.
</us-gaap:SubsequentEventsTextBlock>
<us-gaap:DebtInstrumentFaceAmount contextRef="i0587c4d2148e4925b35c0e309b68874d_I20220715" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzkwNQ_1244f737-5a93-495b-8aac-20f51cb2f743" unitRef="usd"> 21000000 </us-gaap:DebtInstrumentFaceAmount>
<nmtr:DebtInstrumentAccordionFeatureIncreaseLimit contextRef="i0587c4d2148e4925b35c0e309b68874d_I20220715" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzg4OQ_0177833b-b363-4f56-8a7d-6c550ac7648e" unitRef="usd"> 70000000 </nmtr:DebtInstrumentAccordionFeatureIncreaseLimit>
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="if2048b92b8c1451e9e824a3abc2870d1_D20220715-20220715" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzc3OA_21d14a18-c54e-4909-9743-6177577d660a" unitRef="number"> 0.05 </us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<nmtr:DebtInstrumentInterestRateFloor contextRef="ia5dfa9fe89cc49b0b71f63050e041a84_D20220715-20220715" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzc4Mw_155e02a7-63af-4592-82c8-9d50ee1e949d" unitRef="number"> 0.06 </nmtr:DebtInstrumentInterestRateFloor>
<nmtr:DebtInstrumentInterestRateFloor contextRef="icace22ebd6a7452a8bd96380d32fdb77_D20220715-20220715" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzc5MA_fec4339b-48c0-4249-aa60-aafd0236ef18" unitRef="number"> 0.18 </nmtr:DebtInstrumentInterestRateFloor>
<nmtr:DebtInstrumentCovenantSubsequentFinancingRequirementMinimum contextRef="i3bb3d70043cc48228471250dee324edd_I20230331" decimals="INF" id="id3VybDovL2RvY3MudjEvZG9jOjc3ZGEyMzc2NmRlZTRlOTZhMDZkOTkyMGFiNGE2NWViL3NlYzo3N2RhMjM3NjZkZWU0ZTk2YTA2ZDk5MjBhYjRhNjVlYl82MS9mcmFnOmJlMDEzOTAxY2M5MzRhN2RhZjE4YTUyMzRkY2VlZTkwL3RleHRyZWdpb246YmUwMTM5MDFjYzkzNGE3ZGFmMThhNTIzNGRjZWVlOTBfMTA5OTUxMTYzNzg3Mw_f83f4304-1863-4e29-a120-5bcac7720576" unitRef="usd"> 25000000 </nmtr:DebtInstrumentCovenantSubsequentFinancingRequirementMinimum>
</xbrl>

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/28/23  9 Meters Biopharma, Inc.          10-K/A     12/31/22   12:763K
 3/28/23  9 Meters Biopharma, Inc.          10-K       12/31/22   72:10M
 3/15/23  9 Meters Biopharma, Inc.          424B5                  1:1.2M

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/30/22  9 Meters Biopharma, Inc.          8-K:1,2,3,8 6/30/22   14:1.2M                                   Command Financial
 6/22/22  9 Meters Biopharma, Inc.          8-K:5,9     6/22/22   12:491K
↑Top
Filing Submission 0001551986-22-000091   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 3, 1:02:25.2pm ET